# Paper List of Terms(Rare Disease)
- [25/06] **An Agentic System for Rare Disease Diagnosis with Traceable Reasoning**  
[[Paper](http://arxiv.org/pdf/2506.20430v1)] [[Code/Page](http://raredx.cn/doctor.)] [[TLDR/Notes](#an-agentic-system-for-rare-disease-diagnosis-with-traceable-reasoning)]

- [25/06] **Evaluating Rare Disease Diagnostic Performance in Symptom Checkers: A Synthetic Vignette Simulation Approach**  
[[Paper](http://arxiv.org/pdf/2506.19750v3)] [[Code/Page]()] [[TLDR/Notes](#evaluating-rare-disease-diagnostic-performance-in-symptom-checkers--a-synthetic-vignette-simulation-approach)]

- [25/06] **Quantitative Benchmarking of Anomaly Detection Methods in Digital Pathology**  
[[Paper](http://arxiv.org/pdf/2506.19234v1)] [[Code/Page]()] [[TLDR/Notes](#quantitative-benchmarking-of-anomaly-detection-methods-in-digital-pathology)]

- [25/06] **Benchmarking Foundation Models and Parameter-Efficient Fine-Tuning for Prognosis Prediction in Medical Imaging**  
[[Paper](http://arxiv.org/pdf/2506.18434v1)] [[Code/Page]()] [[TLDR/Notes](#benchmarking-foundation-models-and-parameter-efficient-fine-tuning-for-prognosis-prediction-in-medical-imaging)]

- [25/06] **PhenoKG: Knowledge Graph-Driven Gene Discovery and Patient Insights from Phenotypes Alone**  
[[Paper](http://arxiv.org/pdf/2506.13119v1)] [[Code/Page]()] [[TLDR/Notes](#phenokg--knowledge-graph-driven-gene-discovery-and-patient-insights-from-phenotypes-alone)]

- [25/06] **Conditional diffusion models for guided anomaly detection in brain images using fluid-driven anomaly randomization**  
[[Paper](http://arxiv.org/pdf/2506.10233v1)] [[Code/Page]()] [[TLDR/Notes](#conditional-diffusion-models-for-guided-anomaly-detection-in-brain-images-using-fluid-driven-anomaly-randomization)]

- [25/06] **CXR-LT 2024: A MICCAI challenge on long-tailed, multi-label, and zero-shot disease classification from chest X-ray**  
[[Paper](http://arxiv.org/pdf/2506.07984v1)] [[Code/Page]()] [[TLDR/Notes](#cxr-lt-2024--a-miccai-challenge-on-long-tailed--multi-label--and-zero-shot-disease-classification-from-chest-x-ray)]

- [25/05] **CaseReportBench: An LLM Benchmark Dataset for Dense Information Extraction in Clinical Case Reports**  
[[Paper](http://arxiv.org/pdf/2505.17265v1)] [[Code/Page]()] [[TLDR/Notes](#casereportbench--an-llm-benchmark-dataset-for-dense-information-extraction-in-clinical-case-reports)]

- [25/05] **Decoding Rarity: Large Language Models in the Diagnosis of Rare Diseases**  
[[Paper](http://arxiv.org/pdf/2505.17065v1)] [[Code/Page]()] [[TLDR/Notes](#decoding-rarity--large-language-models-in-the-diagnosis-of-rare-diseases)]

- [25/03] **MODIS: Multi-Omics Data Integration for Small and Unpaired Datasets**  
[[Paper](http://arxiv.org/pdf/2503.18856v1)] [[Code/Page](https://github.com/VILLOUTREIXLab/MODIS.)] [[TLDR/Notes](#modis--multi-omics-data-integration-for-small-and-unpaired-datasets)]



# TLDR/Notes
## an-agentic-system-for-rare-disease-diagnosis-with-traceable-reasoning
### Abstract
Rare diseases collectively affect over 300 million individuals worldwide, yet
timely and accurate diagnosis remains a pervasive challenge. This is largely
due to their clinical heterogeneity, low individual prevalence, and the limited
familiarity most clinicians have with rare conditions. Here, we introduce
DeepRare, the first rare disease diagnosis agentic system powered by a large
language model (LLM), capable of processing heterogeneous clinical inputs. The
system generates ranked diagnostic hypotheses for rare diseases, each
accompanied by a transparent chain of reasoning that links intermediate
analytic steps to verifiable medical evidence.
  DeepRare comprises three key components: a central host with a long-term
memory module; specialized agent servers responsible for domain-specific
analytical tasks integrating over 40 specialized tools and web-scale,
up-to-date medical knowledge sources, ensuring access to the most current
clinical information. This modular and scalable design enables complex
diagnostic reasoning while maintaining traceability and adaptability. We
evaluate DeepRare on eight datasets. The system demonstrates exceptional
diagnostic performance among 2,919 diseases, achieving 100% accuracy for 1013
diseases. In HPO-based evaluations, DeepRare significantly outperforms other 15
methods, like traditional bioinformatics diagnostic tools, LLMs, and other
agentic systems, achieving an average Recall@1 score of 57.18% and surpassing
the second-best method (Reasoning LLM) by a substantial margin of 23.79
percentage points. For multi-modal input scenarios, DeepRare achieves 70.60% at
Recall@1 compared to Exomiser's 53.20% in 109 cases. Manual verification of
reasoning chains by clinical experts achieves 95.40% agreements. Furthermore,
the DeepRare system has been implemented as a user-friendly web application
http://raredx.cn/doctor.
### ğŸŒŸ è®ºæ–‡è§£è¯» | ç”¨å¤§è¯­è¨€æ¨¡å‹æ‰“é€ å¯è¿½æº¯æ¨ç†çš„ç½•è§ç—…è¯Šæ–­æ™ºèƒ½ç³»ç»Ÿ

### ğŸ“Œ èƒŒæ™¯ç—›ç‚¹/æœ¬æ–‡åŠ¨æœº
ç½•è§ç—…åœ¨å…¨çƒå½±å“è¶…3äº¿äººï¼Œä½†åŠæ—¶å‡†ç¡®è¯Šæ–­é¢ä¸´è¯¸å¤šæŒ‘æˆ˜ï¼šä¸´åºŠå¼‚è´¨æ€§å¼ºã€å•ä¸ªç–¾ç—…æ‚£ç—…ç‡ä½ã€åŒ»ç”Ÿå¯¹ç½•è§ç—…ç†Ÿæ‚‰åº¦æœ‰é™ï¼Œæ‚£è€…å¸¸ç»å†æ¼«é•¿â€œè¯Šæ–­ Odysseyâ€ï¼ˆå¹³å‡è¶…5å¹´è½¬è¯Šã€è¯¯è¯Šç­‰ï¼‰ã€‚åŒæ—¶ï¼Œå¼€å‘ç½•è§ç—…AIè¯Šæ–­ç³»ç»Ÿå­˜åœ¨å¤šéš¾ç‚¹ï¼šéœ€å¤šå­¦ç§‘çŸ¥è¯†å¤„ç†å¤æ‚å¼‚è´¨ç—‡çŠ¶ã€ç—…ä¾‹å°‘æ˜“è¿‡æ‹Ÿåˆã€çŸ¥è¯†æ›´æ–°å¿«éœ€é«˜æ•ˆæ•´åˆã€è¯Šæ–­éœ€é€æ˜å¯è¿½æº¯ä»¥è·ä¸´åºŠä¿¡ä»»ã€‚è€Œå¤§è¯­è¨€æ¨¡å‹é©±åŠ¨çš„æ™ºèƒ½ä½“ç³»ç»Ÿä¸ºè§£å†³è¿™äº›éš¾é¢˜æä¾›äº†æ–°å¯èƒ½ã€‚

### ğŸš€ æ ¸å¿ƒæ–¹æ³•ï¼ˆä»‹ç»æœ¬æ–‡çš„å‡ ä¸ªåˆ›æ–°ç‚¹ï¼‰
ğŸ’¡ åˆ›æ–°ç‚¹1ï¼šæå‡ºDeepRareç³»ç»Ÿæ¶æ„  
DeepRareæ˜¯é¦–ä¸ªåŸºäºå¤§è¯­è¨€æ¨¡å‹ï¼ˆLLMï¼‰çš„ç½•è§ç—…è¯Šæ–­æ™ºèƒ½ä½“ç³»ç»Ÿï¼Œèƒ½å¤„ç†å¼‚æ„ä¸´åºŠè¾“å…¥ï¼ˆè‡ªç”±æ–‡æœ¬ä¸´åºŠæè¿°ã€ç»“æ„åŒ–äººç±»è¡¨å‹æœ¬ä½“HPOæœ¯è¯­ã€åŸºå› æ£€æµ‹VCFæ ¼å¼ç»“æœï¼‰ã€‚ç³»ç»Ÿç”±ä¸‰å±‚æ„æˆï¼šæ ¸å¿ƒæ˜¯å¸¦è®°å¿†åº“çš„ä¸­å¤®å®¿ä¸»ï¼ˆåè°ƒè¯Šæ–­æµç¨‹ã€ä¿ç•™ä¸Šä¸‹æ–‡ï¼‰ï¼›å‘¨å›´æ˜¯å¤šä¸ªä¸“ç”¨æ™ºèƒ½ä½“æœåŠ¡å™¨ï¼ˆè´Ÿè´£è¡¨å‹æå–ã€å˜å¼‚ä¼˜å…ˆçº§æ’åºç­‰é¢†åŸŸä»»åŠ¡ï¼‰ï¼›æœ€å¤–å±‚æ˜¯ç²¾é€‰å’Œç½‘ç»œè§„æ¨¡çš„å¤–éƒ¨æ•°æ®æºï¼ˆç¡®ä¿è·å–æœ€æ–°ä¸´åºŠè¯æ®ï¼‰ï¼Œè¿˜åŠ å…¥è‡ªåæ€è¯Šæ–­å¾ªç¯ï¼Œè¿­ä»£è¯„ä¼°ä¸­é—´å‡è®¾é™ä½è¯¯è¯Šå’ŒLLMå¹»è§‰é£é™©ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹2ï¼šå®ç°å¯è¿½æº¯æ¨ç†ä¸å¤šæ¨¡æ€å¤„ç†  
ç³»ç»Ÿç”Ÿæˆå¸¦æ’åçš„ç½•è§ç—…è¯Šæ–­å‡è®¾ï¼Œæ¯ä¸ªå‡è®¾éƒ½æœ‰é€æ˜æ¨ç†é“¾ï¼Œå°†åˆ†ææ­¥éª¤ä¸å¯éªŒè¯åŒ»å­¦è¯æ®å…³è”ï¼Œæ”¯æ’‘ä¸´åºŠä¿¡ä»»ä¸AI - äººç±»åä½œã€‚åŒæ—¶æ”¯æŒè‡ªç”±æ–‡æœ¬ã€HPOã€åŸºå› æ£€æµ‹ç»“æœç­‰å¤šæ¨¡æ€è¾“å…¥ï¼Œé€‚é…çœŸå®å¤æ‚ä¸´åºŠåœºæ™¯ã€‚  

### ğŸ“ˆ å®éªŒç»“æœ
åœ¨8ä¸ªæ•°æ®é›†ï¼ˆæ¶µç›–äºšæ¬§ç¾ç—…ä¾‹ã€14ä¸ªåŒ»å­¦ä¸“ç§‘ã€2919ç§ç–¾ç—…ï¼‰è¯„ä¼°ä¸­è¡¨ç°å“è¶Šï¼š2919ç§ç–¾ç—…é‡Œ1013ç§å®ç°100%è¯Šæ–­å‡†ç¡®ç‡ï¼›HPOè¯„ä¼°ä»»åŠ¡ä¸­ï¼Œæ¯”15ç§æ–¹æ³•ï¼ˆä¼ ç»Ÿå·¥å…·ã€LLMã€å…¶ä»–æ™ºèƒ½ä½“ç³»ç»Ÿï¼‰æ˜¾è‘—æ›´ä¼˜ï¼ŒRecall@1è¾¾57.18%ï¼Œæ¯”æ¬¡ä¼˜æ–¹æ³•é«˜23.79ä¸ªç™¾åˆ†ç‚¹ï¼›å¤šæ¨¡æ€è¾“å…¥åœºæ™¯ï¼ˆ109ä¾‹å…¨å¤–æ˜¾å­æµ‹åºç—…ä¾‹ï¼‰ä¸­Recall@1è¾¾70.60%ï¼Œè¿œè¶…Exomiserçš„53.20%ï¼›ä¸´åºŠä¸“å®¶æ‰‹åŠ¨éªŒè¯æ¨ç†é“¾ï¼Œä¸€è‡´æ€§è¾¾95.40%ï¼Œè¯æ˜æ¨ç†åŒ»å­¦æœ‰æ•ˆæ€§ä¸å¯è¿½æº¯æ€§ã€‚  

### ğŸ’¬ å¯å€Ÿé‰´ä¹‹å¤„
1. æ¶æ„è®¾è®¡ï¼šæ¨¡å—åŒ–ã€å¯æ‰©å±•çš„æ™ºèƒ½ä½“ç³»ç»Ÿæ¶æ„ï¼Œæ•´åˆé¢†åŸŸå·¥å…·ä¸åŠ¨æ€çŸ¥è¯†æºï¼Œä¸ºå¤æ‚ä»»åŠ¡ï¼ˆå¦‚åŒ»ç–—è¯Šæ–­ï¼‰çš„AIç³»ç»Ÿè®¾è®¡æä¾›å‚è€ƒï¼Œå¹³è¡¡æ¨ç†å¤æ‚åº¦ä¸å¯è¿½æº¯ã€é€‚åº”æ€§ã€‚  
2. å¤šæ¨¡æ€ä¸å¯è§£é‡Šæ€§ï¼šåœ¨å¤„ç†å¤šæ¨¡æ€å¼‚æ„æ•°æ®åŠä¸ºAIè¾“å‡ºæ·»åŠ å¯è¿½æº¯æ¨ç†é“¾æ–¹é¢ï¼Œä¸ºåŒ»ç–—ç­‰å¼ºç›‘ç®¡ã€éœ€ä¿¡ä»»é¢†åŸŸçš„AIåº”ç”¨æä¾›èŒƒå¼ï¼ŒåŠ©åŠ›äººæœºåä½œã€‚  
3. è¯„ä¼°ç»´åº¦ï¼šä»å‡†ç¡®ç‡ã€å¤šæ–¹æ³•å¯¹æ¯”ã€ä¸“å®¶éªŒè¯ç­‰å¤šç»´åº¦éªŒè¯ç³»ç»Ÿï¼Œä¸ºåŒç±»åŒ»ç–—AIç³»ç»Ÿè¯„ä¼°æä¾›å…¨é¢æ€è·¯ã€‚

## evaluating-rare-disease-diagnostic-performance-in-symptom-checkers--a-synthetic-vignette-simulation-approach
### Abstract
Symptom Checkers (SCs) provide medical information tailored to user symptoms.
A critical challenge in SC development is preventing unexpected performance
degradation for individual diseases, especially rare diseases, when updating
algorithms. This risk stems from the lack of practical pre-deployment
evaluation methods. For rare diseases, obtaining sufficient evaluation data
from user feedback is difficult. To evaluate the impact of algorithm updates on
the diagnostic performance for individual rare diseases before deployment, this
study proposes and validates a novel Synthetic Vignette Simulation Approach.
This approach aims to enable this essential evaluation efficiently and at a low
cost. To estimate the impact of algorithm updates, we generated synthetic
vignettes from disease-phenotype annotations in the Human Phenotype Ontology
(HPO), a publicly available knowledge base for rare diseases curated by
experts. Using these vignettes, we simulated SC interviews to predict changes
in diagnostic performance. The effectiveness of this approach was validated
retrospectively by comparing the predicted changes with actual performance
metrics using the R-squared ($R^2$) coefficient. Our experiment, covering eight
past algorithm updates for rare diseases, showed that the proposed method
accurately predicted performance changes for diseases with phenotype frequency
information in HPO (n=5). For these updates, we found a strong correlation for
both Recall@8 change ($R^2$ = 0.83,$p$ = 0.031) and Precision@8 change ($R^2$ =
0.78,$p$ = 0.047). Our proposed method enables the pre-deployment evaluation of
SC algorithm changes for individual rare diseases. This evaluation is based on
a publicly available medical knowledge database created by experts, ensuring
transparency and explainability for stakeholders. Additionally, SC developers
can efficiently improve diagnostic performance at a low cost.
### ğŸŒŸ è®ºæ–‡è§£è¯» | ç½•è§ç—…ç—‡çŠ¶æ£€æŸ¥å™¨è¯Šæ–­æ€§èƒ½è¯„ä¼°ï¼šåˆæˆç—…ä¾‹æ¨¡æ‹Ÿæ–°æ–¹æ³•

### ğŸ“Œ èƒŒæ™¯ç—›ç‚¹/æœ¬æ–‡åŠ¨æœº
åœ¨æ•°å­—å¥åº·é¢†åŸŸï¼Œç—‡çŠ¶æ£€æŸ¥å™¨ï¼ˆSCsï¼‰èƒ½ä¾æ®ç”¨æˆ·ç—‡çŠ¶æä¾›ä¸ªæ€§åŒ–åŒ»ç–—ä¿¡æ¯ï¼Œå¯¹ç½•è§ç—…æ—©æœŸè¯Šæ–­ä¹Ÿæœ‰é‡è¦æ„ä¹‰ã€‚ä½†SCsç®—æ³•æ›´æ–°æ—¶ï¼Œæ˜“å‡ºç°ç‰¹å®šç–¾ç—…ï¼ˆå°¤å…¶æ˜¯ç½•è§ç—…ï¼‰è¯Šæ–­æ€§èƒ½æ„å¤–ä¸‹é™çš„é—®é¢˜ã€‚åŸå› åœ¨äºç¼ºä¹å®ç”¨çš„éƒ¨ç½²å‰è¯„ä¼°æ–¹æ³•ï¼šç½•è§ç—…éš¾ä»ç”¨æˆ·åé¦ˆè·å–è¶³é‡è¯„ä¼°æ•°æ®ï¼Œäººå·¥åˆ¶ä½œå¤§é‡ä¸´åºŠç—…ä¾‹æˆæœ¬é«˜ä¸”ä¸ç°å®ï¼ŒåŒæ—¶ç”¨ç—…ä¾‹æŠ¥å‘Šæ„å»ºè¯„ä¼°æ•°æ®é›†ä¹Ÿå­˜åœ¨è¦†ç›–ä¸å…¨é¢ç­‰ç¼ºé™·ã€‚å› æ­¤ï¼ŒäºŸéœ€ä¸€ç§é«˜æ•ˆä½æˆæœ¬çš„æ–¹æ³•ï¼Œåœ¨éƒ¨ç½²å‰è¯„ä¼°ç®—æ³•æ›´æ–°å¯¹ç½•è§ç—…è¯Šæ–­æ€§èƒ½çš„å½±å“ã€‚

### ğŸš€ æ ¸å¿ƒæ–¹æ³•ï¼ˆä»‹ç»æœ¬æ–‡çš„å‡ ä¸ªåˆ›æ–°ç‚¹ï¼‰
ğŸ’¡ åˆ›æ–°ç‚¹1ï¼šæå‡ºåˆæˆç—…ä¾‹æ¨¡æ‹Ÿæ–¹æ³•  
åˆ©ç”¨ä¸“å®¶ç¼–çº‚çš„å…¬å¼€ç½•è§ç—…çŸ¥è¯†åº“â€”â€”äººç±»è¡¨å‹æœ¬ä½“ï¼ˆHPOï¼‰ä¸­çš„ç–¾ç—… - è¡¨å‹æ³¨é‡Šç”Ÿæˆåˆæˆç—…ä¾‹ã€‚HPOåŒ…å«ç–¾ç—…ä¸­å‡ºç°çš„ä¸´åºŠè¡¨å‹åŠå…¶é¢‘ç‡ä¿¡æ¯ï¼ŒåŸºäºæ­¤ç”Ÿæˆçš„åˆæˆç—…ä¾‹å¯ä½œä¸ºSCsè¾“å…¥ï¼Œæ¨¡æ‹Ÿé—®è¯Šè¿‡ç¨‹æ¥é¢„ä¼°ç®—æ³•æ›´æ–°å¯¹è¯Šæ–­æ€§èƒ½çš„å½±å“ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹2ï¼šå…¼é¡¾é€æ˜å¯è§£é‡Šä¸æˆæœ¬æ•ˆç›ŠåŠé€‚åº”æ€§  
è¯„ä¼°ä¾èµ–ä¸“å®¶ç»´æŠ¤çš„å…¬å¼€åŒè¡Œè¯„å®¡åŒ»ç–—çŸ¥è¯†åº“ï¼Œä¸ºåˆ©ç›Šç›¸å…³è€…æä¾›é«˜é€æ˜åº¦ä¸å¯è§£é‡Šæ€§ï¼›åˆæˆç—…ä¾‹æ¯”ä¼ ç»Ÿä¸´åºŠç—…ä¾‹ç”Ÿæˆæˆæœ¬ä½å¾—å¤šï¼›æ–¹æ³•ä¸ä¾èµ–SCsç‰¹å®šAIæˆ–ç®—æ³•ï¼Œé€‚é…ä¸åŒSCså¼€å‘è€…ï¼Œå¯¹å†…éƒ¨å®ç°å˜æ›´é²æ£’ï¼Œæ–¹ä¾¿å¼€å‘è€…ä½¿ç”¨ã€‚  

### ğŸ“ˆ å®éªŒç»“æœ
å®éªŒè¦†ç›–8æ¬¡ç½•è§ç—…ç®—æ³•æ›´æ–°ï¼Œç»“æœæ˜¾ç¤ºï¼šå¯¹äºHPOä¸­æœ‰è¡¨å‹é¢‘ç‡ä¿¡æ¯çš„ç–¾ç—…ï¼ˆn = 5ï¼‰ï¼Œè¯¥æ–¹æ³•èƒ½å‡†ç¡®é¢„æµ‹æ€§èƒ½å˜åŒ–ã€‚Recall@8å˜åŒ–çš„RÂ²è¾¾0.83ï¼ˆp = 0.031ï¼‰ï¼ŒPrecision@8å˜åŒ–çš„RÂ²è¾¾0.78ï¼ˆp = 0.047ï¼‰ï¼ŒäºŒè€…å‡æœ‰å¼ºç›¸å…³æ€§ï¼›è€ŒHPOä¸­æ— é¢‘ç‡æ•°æ®çš„ç–¾ç—…ï¼ˆn = 3ï¼‰é¢„æµ‹è¯¯å·®å¤§ï¼Œå‡¸æ˜¾é¢‘ç‡ä¿¡æ¯å…³é”®ä½œç”¨ã€‚å¦å¤–ï¼Œå°†HPOè¡¨å‹æ˜ å°„åˆ°SCsç—‡çŠ¶å¹³å‡æ¯ç—…çº¦éœ€2å°æ—¶ã€‚  

### ğŸ’¬ å¯å€Ÿé‰´ä¹‹å¤„
è¯¥æ–¹æ³•ä¸ºSCsç½•è§ç—…ç®—æ³•æ›´æ–°æä¾›éƒ¨ç½²å‰è¯„ä¼°é€”å¾„ï¼ŒåŸºäºå…¬å¼€ä¸“å®¶åŒ»ç–—çŸ¥è¯†åº“ä¿éšœé€æ˜å¯è§£é‡Šæ€§ï¼Œè¿˜èƒ½è®©å¼€å‘è€…ä½æˆæœ¬é«˜æ•ˆæå‡ç½•è§ç—…è¯Šæ–­æ€§èƒ½ã€‚å¯¹åŒ»ç–—AIé¢†åŸŸï¼Œå°¤å…¶æ˜¯ç—‡çŠ¶æ£€æŸ¥ç±»å·¥å…·ç ”å‘ï¼Œåœ¨è¯„ä¼°æ–¹æ³•åˆ›æ–°ã€åŒ»ç–—çŸ¥è¯†åº“åˆ©ç”¨ç­‰æ–¹é¢æä¾›äº†æ–°æ€è·¯ï¼Œä¸ºè§£å†³ç½•è§ç—…è¿™ç±»å°ä¼—ä½†å…³é”®åœºæ™¯çš„ç®—æ³•è¯„ä¼°éš¾é¢˜ç»™å‡ºäº†å¯è¡Œæ–¹æ¡ˆã€‚

## quantitative-benchmarking-of-anomaly-detection-methods-in-digital-pathology
### Abstract
Anomaly detection has been widely studied in the context of industrial defect
inspection, with numerous methods developed to tackle a range of challenges. In
digital pathology, anomaly detection holds significant potential for
applications such as rare disease identification, artifact detection, and
biomarker discovery. However, the unique characteristics of pathology images,
such as their large size, multi-scale structures, stain variability, and
repetitive patterns, introduce new challenges that current anomaly detection
algorithms struggle to address. In this quantitative study, we benchmark over
20 classical and prevalent anomaly detection methods through extensive
experiments. We curated five digital pathology datasets, both real and
synthetic, to systematically evaluate these approaches. Our experiments
investigate the influence of image scale, anomaly pattern types, and training
epoch selection strategies on detection performance. The results provide a
detailed comparison of each method's strengths and limitations, establishing a
comprehensive benchmark to guide future research in anomaly detection for
digital pathology images.
```
### ğŸŒŸ è®ºæ–‡è§£è¯» | æ•°å­—ç—…ç†ä¸­å¼‚å¸¸æ£€æµ‹æ–¹æ³•çš„å®šé‡åŸºå‡†æµ‹è¯•

### ğŸ“Œ èƒŒæ™¯ç—›ç‚¹/æœ¬æ–‡åŠ¨æœº
å¼‚å¸¸æ£€æµ‹åœ¨å·¥ä¸šç¼ºé™·æ£€æµ‹ç­‰é¢†åŸŸå·²è¢«å¹¿æ³›ç ”ç©¶ï¼Œä½†åœ¨æ•°å­—ç—…ç†é¢†åŸŸï¼Œç—…ç†å›¾åƒå…·æœ‰å¤§å°ºå¯¸ã€å¤šå°ºåº¦ç»“æ„ã€æŸ“è‰²å˜å¼‚æ€§å’Œé‡å¤æ¨¡å¼ç­‰ç‹¬ç‰¹ç‰¹å¾ï¼Œå½“å‰å¼‚å¸¸æ£€æµ‹ç®—æ³•éš¾ä»¥åº”å¯¹è¿™äº›æ–°æŒ‘æˆ˜ã€‚è€Œå¼‚å¸¸æ£€æµ‹åœ¨æ•°å­—ç—…ç†ä¸­å¯¹ç½•è§ç—…è¯†åˆ«ã€ä¼ªå½±æ£€æµ‹å’Œç”Ÿç‰©æ ‡å¿—ç‰©å‘ç°ç­‰åº”ç”¨æœ‰å¾ˆå¤§æ½œåŠ›ï¼Œå› æ­¤éœ€è¦å¯¹ç°æœ‰å¼‚å¸¸æ£€æµ‹æ–¹æ³•åœ¨æ•°å­—ç—…ç†åœºæ™¯ä¸‹è¿›è¡Œç³»ç»Ÿè¯„ä¼°ã€‚

### ğŸš€ æ ¸å¿ƒæ–¹æ³•ï¼ˆä»‹ç»æœ¬æ–‡çš„å‡ ä¸ªåˆ›æ–°ç‚¹ï¼‰
ğŸ’¡ åˆ›æ–°ç‚¹1ï¼šå¤§è§„æ¨¡æ–¹æ³• benchmarking
å¯¹23ç§ç»å…¸å’Œå‰æ²¿çš„å¼‚å¸¸æ£€æµ‹æ–¹æ³•ï¼Œåœ¨åˆæˆå’ŒçœŸå®çš„æ•°å­—ç—…ç†å›¾åƒä¸Šè¿›è¡ŒåŸºå‡†æµ‹è¯•ï¼Œè¿™äº›å›¾åƒå…·æœ‰ä¸åŒçš„å¼‚å¸¸æ¨¡å¼ä»¥å®ç°å…¨é¢è¯„ä¼°ã€‚
ğŸ’¡ åˆ›æ–°ç‚¹2ï¼šæ¢ç´¢å…³é”®å½±å“å› ç´ 
å®éªŒæ¢ç´¢äº†æ•°å­—ç—…ç†ä¸­å¼‚å¸¸æ£€æµ‹æ€§èƒ½çš„å…³é”®å½±å“å› ç´ ï¼ŒåŒ…æ‹¬å›¾åƒå°ºåº¦ã€åå‘å¼‚å¸¸æ¨¡å¼ä»¥åŠè®­ç»ƒè½®æ¬¡é€‰æ‹©ç­–ç•¥ç­‰ï¼Œè¿™äº›åœ¨ä¹‹å‰ç ”ç©¶ä¸­å¾ˆå°‘è¢«è®¨è®ºã€‚
ğŸ’¡ åˆ›æ–°ç‚¹3ï¼šé’ˆå¯¹æ€§çš„é¢†åŸŸåˆ†æ
å›é¡¾ç°æœ‰å¼‚å¸¸æ£€æµ‹æ–¹æ³•åœ¨ç—…ç†å›¾åƒä¸Šçš„åº”ç”¨ï¼Œç»“åˆå®éªŒç»“æœä¸ºè¯¥é¢†åŸŸæœªæ¥ç ”ç©¶æä¾›æœ‰ä»·å€¼çš„è§è§£ï¼›åŒæ—¶æ€»ç»“ç—…ç†å›¾åƒå¼‚å¸¸æ£€æµ‹çš„é¢†åŸŸç‰¹å®šç‰¹å¾ï¼Œå¼•å…¥ä¸ºåˆ†æé‡èº«å®šåˆ¶çš„çœŸå®å’Œåˆæˆæ•°æ®é›†ã€‚

### ğŸ“ˆ å®éªŒç»“æœ
é€šè¿‡ç²¾å¿ƒç­–åˆ’çš„5ä¸ªçœŸå®ä¸åˆæˆæ•°å­—ç—…ç†æ•°æ®é›†ï¼Œç³»ç»Ÿè¯„ä¼°è¿™äº›å¼‚å¸¸æ£€æµ‹æ–¹æ³•ã€‚å®éªŒæ¢ç©¶å›¾åƒå°ºåº¦ã€å¼‚å¸¸æ¨¡å¼ç±»å‹å’Œè®­ç»ƒè½®æ¬¡é€‰æ‹©ç­–ç•¥å¯¹æ£€æµ‹æ€§èƒ½çš„å½±å“ï¼Œè¯¦ç»†å¯¹æ¯”äº†æ¯ç§æ–¹æ³•çš„ä¼˜åŠ¿å’Œå±€é™æ€§ï¼Œå»ºç«‹äº†å…¨é¢çš„åŸºå‡†ä»¥æŒ‡å¯¼æ•°å­—ç—…ç†å›¾åƒå¼‚å¸¸æ£€æµ‹çš„æœªæ¥ç ”ç©¶ã€‚

### ğŸ’¬ å¯å€Ÿé‰´ä¹‹å¤„
å¯¹äºç ”ç©¶æ•°å­—ç—…ç†ä¸å¼‚å¸¸æ£€æµ‹äº¤å‰é¢†åŸŸçš„å­¦è€…ï¼Œæœ¬æ–‡æä¾›äº†ä¸åŒæ–¹æ³•åœ¨ç—…ç†å›¾åƒä¸Šçš„æ€§èƒ½è¡¨ç°å‚è€ƒï¼Œæ˜ç¡®äº†å„æ–¹æ³•é€‚ç”¨åœºæ™¯ï¼›å…¶å¯¹å›¾åƒå°ºåº¦ã€è®­ç»ƒç­–ç•¥ç­‰å› ç´ çš„æ¢ç©¶æ€è·¯ï¼Œä¹Ÿä¸ºåç»­ä¼˜åŒ–å¼‚å¸¸æ£€æµ‹ç®—æ³•åœ¨ç‰¹å®šé¢†åŸŸæ€§èƒ½æä¾›äº†å¯å€Ÿé‰´çš„å®éªŒè®¾è®¡æ–¹å‘ï¼›åŒæ—¶å¯¹ç—…ç†å›¾åƒé¢†åŸŸç‰¹å¾çš„æ€»ç»“ï¼Œæœ‰åŠ©äºç ”ç©¶è€…æ›´æœ‰é’ˆå¯¹æ€§åœ°æ”¹è¿›ç®—æ³•ä»¥é€‚é…ç—…ç†å›¾åƒçš„ç‹¬ç‰¹æ€§ã€‚
```

## benchmarking-foundation-models-and-parameter-efficient-fine-tuning-for-prognosis-prediction-in-medical-imaging
### Abstract
Artificial Intelligence (AI) holds significant promise for improving
prognosis prediction in medical imaging, yet its effective application remains
challenging. In this work, we introduce a structured benchmark explicitly
designed to evaluate and compare the transferability of Convolutional Neural
Networks and Foundation Models in predicting clinical outcomes in COVID-19
patients, leveraging diverse publicly available Chest X-ray datasets. Our
experimental methodology extensively explores a wide set of fine-tuning
strategies, encompassing traditional approaches such as Full Fine-Tuning and
Linear Probing, as well as advanced Parameter-Efficient Fine-Tuning methods
including Low-Rank Adaptation, BitFit, VeRA, and IA3. The evaluations were
conducted across multiple learning paradigms, including both extensive
full-data scenarios and more clinically realistic Few-Shot Learning settings,
which are critical for modeling rare disease outcomes and rapidly emerging
health threats. By implementing a large-scale comparative analysis involving a
diverse selection of pretrained models, including general-purpose architectures
pretrained on large-scale datasets such as CLIP and DINOv2, to
biomedical-specific models like MedCLIP, BioMedCLIP, and PubMedCLIP, we
rigorously assess each model's capacity to effectively adapt and generalize to
prognosis tasks, particularly under conditions of severe data scarcity and
pronounced class imbalance. The benchmark was designed to capture critical
conditions common in prognosis tasks, including variations in dataset size and
class distribution, providing detailed insights into the strengths and
limitations of each fine-tuning strategy. This extensive and structured
evaluation aims to inform the practical deployment and adoption of robust,
efficient, and generalizable AI-driven solutions in real-world clinical
prognosis prediction workflows.
### ğŸŒŸ è®ºæ–‡è§£è¯» | åŒ»ç–—å½±åƒé¢„åé¢„æµ‹ä¸­åŸºç¡€æ¨¡å‹ä¸é«˜æ•ˆå‚æ•°å¾®è°ƒçš„ benchmark ç ”ç©¶

### ğŸ“Œ èƒŒæ™¯ç—›ç‚¹/æœ¬æ–‡åŠ¨æœº
AI åœ¨åŒ»ç–—å½±åƒé¢„åé¢„æµ‹é¢†åŸŸè™½å‰æ™¯å¹¿é˜”ï¼Œä½†æœ‰æ•ˆåº”ç”¨ä»å…·æŒ‘æˆ˜ã€‚é¢„åä»»åŠ¡æ¯”è¯Šæ–­ä»»åŠ¡æ›´å¤æ‚ä¸”ç ”ç©¶è¾ƒå°‘ï¼Œæ•°æ®å­˜åœ¨æ—¶é—´ç»“æ„ã€é«˜è´¨é‡æ ‡æ³¨å°‘ç­‰é—®é¢˜ã€‚ä¼ ç»Ÿå·ç§¯ç¥ç»ç½‘ç»œï¼ˆCNNsï¼‰åœ¨å¤„ç†é¢„åä»»åŠ¡æ—¶ï¼Œå­˜åœ¨æ•æ‰é•¿ç¨‹ä¾èµ–èƒ½åŠ›æœ‰é™ã€å…¨å¾®è°ƒè¦æ±‚é«˜é€‚é…æ€§ä¸è¶³ç­‰å±€é™ï¼›è‡ªç›‘ç£å­¦ä¹ å‚¬ç”Ÿçš„åŸºç¡€æ¨¡å‹ï¼ˆFMsï¼‰åœ¨é¢„åé¢†åŸŸæ¢ç´¢æœ‰é™ï¼Œå› é¢„åæ•°æ®é›†æ ·æœ¬ç¨€ç¼ºã€ç±»åˆ«ä¸å¹³è¡¡ç­‰é—®é¢˜ï¼Œä¼ ç»Ÿé€‚é…æŠ€æœ¯éš¾åº”å¯¹ï¼›å…¨å¾®è°ƒå­˜åœ¨å¯æ‰©å±•æ€§å’Œæ•°æ®æ•ˆç‡å±€é™ï¼Œè€Œå‚æ•°é«˜æ•ˆå¾®è°ƒï¼ˆPEFTï¼‰å’Œå°‘æ ·æœ¬å­¦ä¹ ï¼ˆFSLï¼‰æ˜¯æœ‰æ½œåŠ›çš„è§£å†³æ–¹å‘ï¼Œä½†åœ¨åŒ»ç–—é¢„åä¸­ç›¸å…³æ¢ç´¢ä¸è¶³ã€‚å› æ­¤ï¼Œæœ¬æ–‡æ—¨åœ¨æ„å»ºç»“æ„åŒ–åŸºå‡†ï¼Œè¯„ä¼°ä¸åŒé¢„è®­ç»ƒæ¨¡å‹ä¸å¾®è°ƒç­–ç•¥åœ¨åŒ»ç–—é¢„åçš„è¡¨ç°ã€‚

### ğŸš€ æ ¸å¿ƒæ–¹æ³•ï¼ˆä»‹ç»æœ¬æ–‡çš„å‡ ä¸ªåˆ›æ–°ç‚¹ï¼‰
ğŸ’¡ åˆ›æ–°ç‚¹1ï¼šå…¨é¢å¯¹æ¯”åŸºç¡€æ¨¡å‹ä¸ CNN æ¶æ„  
æ„å»ºç³»ç»ŸåŸºå‡†ï¼Œå¯¹æ¯” PEFT æŠ€æœ¯ä¸ä¼ ç»Ÿå¾®è°ƒç­–ç•¥ï¼ˆå¦‚å…¨å¾®è°ƒ FFTã€çº¿æ€§æ¢æµ‹ LPï¼‰ï¼Œæ¶µç›–é€šç”¨é¢„è®­ç»ƒæ¨¡å‹ï¼ˆå¦‚ ResNet18ï¼‰å’ŒåŒ»ç–—é¢†åŸŸé¢„è®­ç»ƒæ¨¡å‹ï¼ˆå¦‚ PubMedCLIPï¼‰ï¼Œèšç„¦é¢„åé¢„æµ‹ä»»åŠ¡ï¼Œæ¢ç©¶å“ªäº›ç­–ç•¥å¯¹æ•°æ®ç¨€ç¼ºå’Œç±»åˆ«ä¸å¹³è¡¡æ›´é²æ£’ï¼Œè¿™ä¸¤ç±»æ˜¯é¢„åå»ºæ¨¡å…³é”®æŒ‘æˆ˜ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹2ï¼šæ¢ç´¢åŸºç¡€æ¨¡å‹åœ¨é¢„åä»»åŠ¡çš„ PEFT åº”ç”¨  
é’ˆå¯¹åŒ»ç–—å½±åƒä¸­ CNN ç ”ç©¶å¤šã€FMs åœ¨é¢„åé¢„æµ‹æ¢ç´¢å°‘çš„ç°çŠ¶ï¼Œå¯¹ FMs å¼€å±•å¯¹æ¯”è¯„ä¼°ï¼Œåˆ†æ PEFTã€LPã€FFT ç­‰ç­–ç•¥ï¼Œç¡®å®šåœ¨è®¡ç®—æˆæœ¬å’Œé¢„æµ‹æ€§èƒ½é—´æœ€ä¼˜æƒè¡¡çš„æ–¹æ³•ä¸æ¶æ„ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹3ï¼šå¼€å±•é¢„åå»ºæ¨¡ä¸­çš„å°‘æ ·æœ¬å­¦ä¹ åˆ†æ  
ç³»ç»Ÿåˆ†æ FSLï¼Œç»“åˆåŒ»ç–—åœºæ™¯ä¸­æ•°æ®ç¨€ç¼ºç‰¹ç‚¹ï¼Œæ¢ç´¢åœ¨æå°‘æ ‡æ³¨æ ·æœ¬ä¸‹æ¨¡å‹æ³›åŒ–èƒ½åŠ›ï¼Œä¸”è€ƒè™‘å°† PEFT èå…¥ FSL  pipeline æå‡èµ„æºå—é™ç¯å¢ƒä¸‹çš„é€‚é…æ•ˆç‡ï¼Œä¸ºæ ‡æ³¨æ•°æ®éš¾è·å–çš„åŒ»ç–— AI åº”ç”¨æä¾›æ–¹æ¡ˆã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹4ï¼šæ„å»ºé’ˆå¯¹é¢„åä»»åŠ¡çš„ç»“æ„åŒ–åŸºå‡†  
ä»¥ COVID - 19 èƒ¸éƒ¨ X å…‰ï¼ˆCXRï¼‰é¢„åä¸ºä¸´åºŠç›¸å…³ä¸”æ ‡å‡†åŒ–çš„ç”¨ä¾‹ï¼Œåˆ©ç”¨å…·æœ‰ä¸åŒç»“æœç±»å‹ã€æ ·æœ¬é‡å’Œä¸å¹³è¡¡ç¨‹åº¦çš„å…¬å…±æ•°æ®é›†ï¼Œæ•æ‰é¢„åä»»åŠ¡ä¸­æ•°æ®é›†å¤§å°ã€ç±»åˆ«åˆ†å¸ƒå˜åŒ–ç­‰å…³é”®æ¡ä»¶ï¼Œä¸ºå„å¾®è°ƒç­–ç•¥å¼ºå¼±é¡¹æä¾›è¯¦ç»†æ´è§ã€‚  

### ğŸ“ˆ å®éªŒç»“æœ
æ–‡ä¸­é€šè¿‡å¤§è§„æ¨¡å¯¹æ¯”åˆ†æï¼Œæ¶‰åŠä»é€šç”¨å¤§è§„æ¨¡æ•°æ®é›†é¢„è®­ç»ƒçš„æ¶æ„ï¼ˆå¦‚ CLIPã€DINOv2ï¼‰åˆ°ç”Ÿç‰©åŒ»å­¦ç‰¹å®šæ¨¡å‹ï¼ˆå¦‚ MedCLIPã€BioMedCLIPã€PubMedCLIPï¼‰ç­‰å¤šæ ·é¢„è®­ç»ƒæ¨¡å‹ï¼Œè¯„ä¼°æ¨¡å‹åœ¨é¢„åä»»åŠ¡ï¼ˆå°¤å…¶æ•°æ®ä¸¥é‡ç¨€ç¼ºå’Œç±»åˆ«ä¸å¹³è¡¡ä¸‹ï¼‰çš„é€‚é…ä¸æ³›åŒ–èƒ½åŠ›ï¼Œæ˜ç¡®å„å¾®è°ƒç­–ç•¥åœ¨ä¸åŒåœºæ™¯ä¸‹çš„è¡¨ç°ï¼Œä¸ºå®é™…ä¸´åºŠé¢„åé¢„æµ‹å·¥ä½œæµä¸­ AI æ–¹æ¡ˆéƒ¨ç½²æä¾›ä¾æ®ï¼Œä½†åŸæ–‡æœªè¯¦ç»†åˆ—å‡ºå…·ä½“å®éªŒæ•°å€¼ç»“æœï¼Œé‡ç‚¹åœ¨æ„å»ºè¯„ä¼°ä½“ç³»ä¸å¯¹æ¯”åˆ†æé€»è¾‘ã€‚

### ğŸ’¬ å¯å€Ÿé‰´ä¹‹å¤„
1. åŸºå‡†æ„å»ºæ€è·¯ï¼šä¸ºç‰¹å®šåŒ»ç–—ä»»åŠ¡ï¼ˆå¦‚ COVID - 19 èƒ¸éƒ¨ X å…‰é¢„åï¼‰æ„å»ºåŒ…å«å¤šæ¨¡å‹ã€å¤šç­–ç•¥ã€å¤šæ•°æ®åœºæ™¯çš„åŸºå‡†ï¼Œå¯ç”¨äºåŒç±»åŒ»ç–— AI ä»»åŠ¡è¯„ä¼°ä½“ç³»æ­å»ºï¼Œæ˜ç¡®ä¸åŒæŠ€æœ¯è·¯çº¿ä¼˜åŠ£ã€‚  
2. æŠ€æœ¯èåˆæ¢ç´¢ï¼šå¯¹ PEFTã€FSL ç­‰æ–°å…´æŠ€æœ¯åœ¨åŒ»ç–—é¢„ååœºæ™¯ç»“åˆåº”ç”¨çš„æ¢ç´¢ï¼Œä¸ºè§£å†³åŒ»ç–—æ•°æ®ç¨€ç¼ºã€æ ‡æ³¨éš¾é—®é¢˜æä¾›æŠ€æœ¯èåˆå‚è€ƒæ–¹å‘ã€‚  
3. æ¨¡å‹ä¸ç­–ç•¥å¯¹æ¯”ç»´åº¦ï¼šå…¨é¢å¯¹æ¯”é€šç”¨ä¸é¢†åŸŸç‰¹å®šé¢„è®­ç»ƒæ¨¡å‹ï¼Œä»¥åŠä¼ ç»Ÿä¸å…ˆè¿›å¾®è°ƒç­–ç•¥ï¼Œè¿™ç§å¤šç»´åº¦å¯¹æ¯”æ–¹å¼å¯æŒ‡å¯¼åç»­åŒ»ç–— AI ç ”ç©¶ä¸­æ¨¡å‹ä¸ç­–ç•¥é€‰å‹ã€‚

## phenokg--knowledge-graph-driven-gene-discovery-and-patient-insights-from-phenotypes-alone
### Abstract
Identifying causative genes from patient phenotypes remains a significant
challenge in precision medicine, with important implications for the diagnosis
and treatment of genetic disorders. We propose a novel graph-based approach for
predicting causative genes from patient phenotypes, with or without an
available list of candidate genes, by integrating a rare disease knowledge
graph (KG). Our model, combining graph neural networks and transformers,
achieves substantial improvements over the current state-of-the-art. On the
real-world MyGene2 dataset, it attains a mean reciprocal rank (MRR) of 24.64\%
and nDCG@100 of 33.64\%, surpassing the best baseline (SHEPHERD) at 19.02\% MRR
and 30.54\% nDCG@100. We perform extensive ablation studies to validate the
contribution of each model component. Notably, the approach generalizes to
cases where only phenotypic data are available, addressing key challenges in
clinical decision support when genomic information is incomplete.
### ğŸŒŸ è®ºæ–‡è§£è¯» | PhenoKGï¼šä»…é è¡¨å‹æ•°æ®ï¼ŒçŸ¥è¯†å›¾è°±é©±åŠ¨çš„è‡´ç—…åŸºå› å‘ç°ä¸æ‚£è€…æ´å¯Ÿ

### ğŸ“Œ èƒŒæ™¯ç—›ç‚¹/æœ¬æ–‡åŠ¨æœº
ç½•è§é—ä¼ ç—…ç»™å…¨çƒåŒ»ç–—ç³»ç»Ÿå¸¦æ¥å·¨å¤§æŒ‘æˆ˜ï¼Œå…¨çƒè¶…3äº¿äººå—å…¶å½±å“ã€‚åœ¨ç²¾å‡†åŒ»ç–—ä¸­ï¼Œä»æ‚£è€…è¡¨å‹è¯†åˆ«è‡´ç—…åŸºå› æ˜¯éš¾é¢˜ï¼Œè¯Šæ–­è¿‡ç¨‹æ¼«é•¿å¤æ‚ï¼ˆå¸¸è¢«ç§°ä¸ºâ€œè¯Šæ–­å¥¥å¾·èµ›â€ï¼‰ï¼Œçº¦70%æ‚£è€…éš¾ä»¥åŠæ—¶ç¡®è¯Šï¼Œè¿‘åŠå­Ÿå¾·å°”é—ä¼ ç—…çš„é—ä¼ ç—…å› ä¸æ˜ã€‚ç°æœ‰è¯Šæ–­æµç¨‹ä¾èµ–ä¸“å®¶æ‰‹åŠ¨æ•´åˆä¸´åºŠä¸åŸºå› ç»„æ•°æ®ï¼Œä¸”å¤šæ•°è¯Šæ–­ pipeline éœ€å…ˆç¡®å®šå€™é€‰åŸºå› åˆ—è¡¨ï¼Œå—é™äºåŒ»å­¦çŸ¥è¯†å’ŒäººåŠ›ã€‚åŒæ—¶ï¼Œæµ‹åºç­‰æŠ€æœ¯è¿›æ­¥åï¼Œç½•è§å­Ÿå¾·å°”ç—…è¯Šæ–­ç‡ä»ä»…30 - 50%ï¼ŒäºŸéœ€èƒ½æ•´åˆå¤šæºç”Ÿç‰©åŒ»å­¦æ•°æ®ã€å…¼å…·å¯è§£é‡Šæ€§ä¸æ™®é€‚æ€§çš„æ–°ä¸€ä»£æ¨¡å‹ï¼Œæ¥è§£å†³åŸºå› ç»„ä¿¡æ¯ä¸å…¨æ—¶ä¸´åºŠå†³ç­–æ”¯æŒçš„éš¾é¢˜ã€‚

### ğŸš€ æ ¸å¿ƒæ–¹æ³•ï¼ˆä»‹ç»æœ¬æ–‡çš„å‡ ä¸ªåˆ›æ–°ç‚¹ï¼‰
ğŸ’¡ åˆ›æ–°ç‚¹1ï¼šæå‡º PhenoKG æ–¹æ³•ï¼Œç»“åˆçŸ¥è¯†å›¾è°±ä¸å›¾ç¥ç»ç½‘ç»œ + Transformerã€‚  
æ„å»ºæ‚£è€…ç‰¹å¼‚æ€§å­å›¾ï¼šåˆ©ç”¨æ‚£è€…è¡¨å‹å’Œç½•è§ç—…çŸ¥è¯†å›¾è°±ï¼ˆKGï¼‰æ„å»ºå­å›¾ï¼Œæ•æ‰æ‚£è€… - ç–¾ç—… - åŸºå› å‹çš„ç‰¹å®šå…³ç³»ï¼›é€šè¿‡å›¾æ³¨æ„åŠ›ç½‘ç»œï¼ˆGATv2ï¼‰ç”ŸæˆèŠ‚ç‚¹åµŒå…¥ï¼Œè¿›è€Œå¾—åˆ°æ‚£è€…å’ŒåŸºå› è¡¨ç¤ºï¼Œç”¨äºé¢„æµ‹æœ€å¯èƒ½çš„è‡´ç—…åŸºå› ï¼Œæ— éœ€æˆ–ä»…éœ€å°‘é‡å€™é€‰åŸºå› åˆ—è¡¨å°±èƒ½å¼€å±•é¢„æµ‹ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹2ï¼šè¦†ç›–å¤šåœºæ™¯ä¸”æ³›åŒ–æ€§å¼ºã€‚  
æ—¢æ”¯æŒæœ‰ä¸“å®¶æ•´ç†çš„å€™é€‰åŸºå› åˆ—è¡¨ï¼ˆçº¦20ä¸ªåŸºå› ï¼‰æ—¶çš„é¢„æµ‹ï¼Œä¹Ÿèƒ½åœ¨æ— å€™é€‰åˆ—è¡¨ï¼ˆä»çº¦8000ä¸ªåŸºå› ä¸­ç­›é€‰ï¼‰æ—¶å·¥ä½œï¼Œå¡«è¡¥äº†åŸºå› ç»„ä¿¡æ¯ä¸å…¨æ—¶ä¸´åºŠå†³ç­–æ”¯æŒçš„ç©ºç™½ï¼Œä¸ºä¸´åºŠæä¾›é¢å¤–çš„å‘ç°å±‚é¢ï¼ˆè™½éœ€åç»­éªŒè¯ï¼Œä½†ç†è®ºä¸Šæ‹“å±•äº†åŸºå› å‘ç°é€”å¾„ï¼‰ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹3ï¼šæ·±å…¥ ablation study éªŒè¯ç»„ä»¶è´¡çŒ®ã€‚  
é€šè¿‡å¤§é‡æ¶ˆèå®éªŒï¼Œæ˜ç¡®æ¨¡å‹å„ç»„ä»¶ï¼ˆå¦‚çŸ¥è¯†å›¾è°±æ•´åˆã€å›¾ç¥ç»ç½‘ç»œä¸ Transformer ç»“åˆç­‰ï¼‰å¯¹æ€§èƒ½çš„è´¡çŒ®ï¼Œè®©æ¨¡å‹è®¾è®¡æ›´å…·å¯è§£é‡Šæ€§ä¸è¯´æœåŠ›ã€‚  


### ğŸ“ˆ å®éªŒç»“æœ
åœ¨çœŸå®ä¸–ç•Œ MyGene2 æ•°æ®é›†ä¸Šï¼ŒPhenoKG å®ç°äº†æ€§èƒ½è¶…è¶Šï¼šå¹³å‡ reciprocal æ’åï¼ˆMRRï¼‰è¾¾24.64%ï¼ŒnDCG@100 ä¸º33.64%ï¼Œè¶…è¿‡å½“å‰æœ€ä¼˜åŸºçº¿æ¨¡å‹ SHEPHERDï¼ˆMRR 19.02%ã€nDCG@100 30.54%ï¼‰ã€‚æ— å€™é€‰åˆ—è¡¨æ—¶ï¼Œæ¨¡å‹å‡†ç¡®ç‡è¾¾15.15 Â± 3.33%ï¼ˆtop æ’åä¸­å‘½ä¸­æ­£ç¡®åŸºå› ï¼‰ï¼›æœ‰å€™é€‰åˆ—è¡¨æ—¶ï¼Œå‡†ç¡®ç‡æå‡è‡³83.96 Â± 1.45%ï¼ŒéªŒè¯äº†å¤šåœºæ™¯ä¸‹çš„æœ‰æ•ˆæ€§ã€‚  


### ğŸ’¬ å¯å€Ÿé‰´ä¹‹å¤„
1. çŸ¥è¯†å›¾è°± + å›¾ç¥ç»ç½‘ç»œçš„èåˆæ€è·¯ï¼šå°†é¢†åŸŸçŸ¥è¯†å›¾è°±ä¸å›¾æ·±åº¦å­¦ä¹ ç»“åˆï¼Œä¸ºç”Ÿç‰©åŒ»å­¦é¢†åŸŸä¸­å¤šæºå¼‚æ„æ•°æ®çš„åˆ©ç”¨æä¾›äº†èŒƒä¾‹ï¼Œå¯å¯å‘å…¶ä»–éœ€æ•´åˆé¢†åŸŸçŸ¥è¯†çš„ AI ä»»åŠ¡ï¼ˆå¦‚è¯ç‰©ç ”å‘ã€ç–¾ç—…åˆ†å‹ç­‰ï¼‰ã€‚  
2. å¤šåœºæ™¯é€‚é…çš„æ¨¡å‹è®¾è®¡ï¼šè€ƒè™‘åˆ°ä¸´åºŠä¸­æ•°æ®å®Œæ•´æ€§å·®å¼‚ï¼Œè®¾è®¡æ”¯æŒâ€œæœ‰æ— å€™é€‰åˆ—è¡¨â€çš„çµæ´»æ¶æ„ï¼Œä¸ºåŒ»ç–— AI å·¥å…·è½åœ°ä¸´åºŠå®é™…åœºæ™¯æä¾›äº†é€‚é…ä¸åŒæ•°æ®æ¡ä»¶çš„å‚è€ƒã€‚  
3. æ¶ˆèå®éªŒçš„ä¸¥è°¨æ€§ï¼šé€šè¿‡ç³»ç»Ÿæ¶ˆèéªŒè¯å„æ¨¡å—ä»·å€¼ï¼Œè¿™ç§â€œæ‹†è§£ - éªŒè¯â€çš„å®éªŒæ€è·¯ï¼Œèƒ½å¸®åŠ©åç»­ç ”ç©¶è€…æ›´æ¸…æ™°ç†è§£æ¨¡å‹å…³é”®ç»„ä»¶çš„ä½œç”¨ï¼Œæå‡ç ”ç©¶çš„å¯å¤ç°æ€§ä¸å¯è§£é‡Šæ€§ã€‚  

## conditional-diffusion-models-for-guided-anomaly-detection-in-brain-images-using-fluid-driven-anomaly-randomization
### Abstract
Supervised machine learning has enabled accurate pathology detection in brain
MRI, but requires training data from diseased subjects that may not be readily
available in some scenarios, for example, in the case of rare diseases.
Reconstruction-based unsupervised anomaly detection, in particular using
diffusion models, has gained popularity in the medical field as it allows for
training on healthy images alone, eliminating the need for large
disease-specific cohorts. These methods assume that a model trained on normal
data cannot accurately represent or reconstruct anomalies. However, this
assumption often fails with models failing to reconstruct healthy tissue or
accurately reconstruct abnormal regions i.e., failing to remove anomalies. In
this work, we introduce a novel conditional diffusion model framework for
anomaly detection and healthy image reconstruction in brain MRI. Our weakly
supervised approach integrates synthetically generated pseudo-pathology images
into the modeling process to better guide the reconstruction of healthy images.
To generate these pseudo-pathologies, we apply fluid-driven anomaly
randomization to augment real pathology segmentation maps from an auxiliary
dataset, ensuring that the synthetic anomalies are both realistic and
anatomically coherent. We evaluate our model's ability to detect pathology,
using both synthetic anomaly datasets and real pathology from the ATLAS
dataset. In our extensive experiments, our model: (i) consistently outperforms
variational autoencoders, and conditional and unconditional latent diffusion;
and (ii) surpasses on most datasets, the performance of supervised inpainting
methods with access to paired diseased/healthy images.
### ğŸŒŸ è®ºæ–‡è§£è¯» | åŸºäºæµä½“é©±åŠ¨å¼‚å¸¸éšæœºåŒ–çš„è„‘å›¾åƒå¼•å¯¼å¼‚å¸¸æ£€æµ‹æ¡ä»¶æ‰©æ•£æ¨¡å‹

### ğŸ“Œ èƒŒæ™¯ç—›ç‚¹/æœ¬æ–‡åŠ¨æœº
åœ¨è„‘MRIå¼‚å¸¸æ£€æµ‹çš„æœ‰ç›‘ç£æœºå™¨å­¦ä¹ åº”ç”¨ä¸­ï¼Œæ•°æ®å¯ç”¨æ€§æ˜¯ä¸€å¤§æŒ‘æˆ˜ï¼Œå°¤å…¶æ˜¯ç½•è§ç—…åœºæ™¯ä¸‹ï¼Œæ‚£ç—…å—è¯•è€…çš„è®­ç»ƒæ•°æ®å¾€å¾€éš¾ä»¥è·å–ã€‚åŸºäºé‡å»ºçš„æ— ç›‘ç£å¼‚å¸¸æ£€æµ‹è™½å¯ä»…ç”¨å¥åº·å›¾åƒè®­ç»ƒï¼Œä½†ç°æœ‰æ–¹æ³•å­˜åœ¨å‡è®¾ä¸æˆç«‹çš„é—®é¢˜ï¼Œå³è®­ç»ƒäºæ­£å¸¸æ•°æ®çš„æ¨¡å‹å¯èƒ½æ— æ³•å‡†ç¡®é‡å»ºå¥åº·ç»„ç»‡æˆ–å¼‚å¸¸åŒºåŸŸã€‚æ­¤å¤–ï¼Œè‡ªåŠ¨ç¼–ç å™¨å­˜åœ¨æ£€æµ‹å¼‚å¸¸èƒ½åŠ›ä¸è¶³ã€ç”Ÿæˆèƒ½åŠ›å·®ç­‰é—®é¢˜ï¼›æ‰©æ•£æ¨¡å‹åœ¨å¤„ç†å¤§å¼‚å¸¸åŒºåŸŸæ—¶ä¹Ÿé¢ä¸´å™ªå£°æ°´å¹³é€‰æ‹©éš¾é¢˜ã€‚å› æ­¤ï¼Œæœ¬æ–‡æ—¨åœ¨æå‡ºæ–°çš„æ¡ä»¶æ‰©æ•£æ¨¡å‹æ¡†æ¶ï¼Œæå‡è„‘MRIå¼‚å¸¸æ£€æµ‹ä¸å¥åº·å›¾åƒé‡å»ºæ•ˆæœã€‚

### ğŸš€ æ ¸å¿ƒæ–¹æ³•ï¼ˆä»‹ç»æœ¬æ–‡çš„å‡ ä¸ªåˆ›æ–°ç‚¹ï¼‰
ğŸ’¡ åˆ›æ–°ç‚¹1ï¼šæå‡ºå«åˆæˆä¼ªç—…ç†å›¾åƒçš„å¼±ç›‘ç£æ¡ä»¶æ‰©æ•£æ¨¡å‹æ¡†æ¶  
è¯¥æ¡†æ¶å°†åˆæˆç”Ÿæˆçš„ä¼ªç—…ç†å›¾åƒæ•´åˆåˆ°å»ºæ¨¡è¿‡ç¨‹ï¼Œä»¥æ›´å¥½å¼•å¯¼å¥åº·å›¾åƒé‡å»ºã€‚é€šè¿‡åœ¨åå‘æ‰©æ•£è¿‡ç¨‹çš„æ¯ä¸ªæ—¶é—´æ­¥çº³å…¥ä¼ªç—…ç†å›¾åƒä¿¡æ¯æ¥è®­ç»ƒæ¨¡å‹ï¼Œä½¿æ¨¡å‹åœ¨è®­ç»ƒæ—¶èƒ½ä¿®æ­£åˆæˆå¼‚å¸¸åŒæ—¶ä¿ç•™å¥åº·ç»„ç»‡åŒºåŸŸã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹2ï¼šæµä½“é©±åŠ¨å¼‚å¸¸éšæœºåŒ–ç”Ÿæˆä¼ªç—…ç†  
åˆ©ç”¨æµä½“é©±åŠ¨å¼‚å¸¸éšæœºåŒ–æ–¹æ³•å¢å¼ºè¾…åŠ©æ•°æ®é›†çš„çœŸå®ç—…ç†åˆ†å‰²å›¾ï¼Œç”Ÿæˆä¼ªç—…ç†ã€‚å°†å¼‚å¸¸æ¨¡å¼éšæœºåŒ–å»ºæ¨¡ä¸ºåå¾®åˆ†æ–¹ç¨‹ï¼ˆPDEï¼‰ä¸»å¯¼çš„å¹³æµ - æ‰©æ•£è¿‡ç¨‹ï¼Œé€šè¿‡å¯æ§é€Ÿåº¦åœºå’Œè¾¹ç•Œæ¡ä»¶ç¡®ä¿æ¨¡æ‹Ÿå¼‚å¸¸åˆç†ï¼Œä¸”ç”Ÿæˆçš„åˆæˆå¼‚å¸¸å…¼å…·çœŸå®æ€§ä¸è§£å‰–å­¦ä¸€è‡´æ€§ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹3ï¼šåŸºäºæ½œåœ¨æ‰©æ•£æ¨¡å‹ï¼ˆLDMï¼‰æ”¹è¿›  
ä»¥LDMä¸ºåŸºç¡€ï¼Œåˆ†ä¸¤é˜¶æ®µè®­ç»ƒã€‚å…ˆç”±ç¼–ç å™¨æ˜ å°„è¾“å…¥å›¾åƒåˆ°æ½œåœ¨è¡¨ç¤ºã€è§£ç å™¨ä»æ½œåœ¨è¡¨ç¤ºé‡å»ºå›¾åƒï¼›å†è®­ç»ƒDDPMå­¦ä¹ æ½œåœ¨è¡¨ç¤ºåˆ†å¸ƒï¼Œå€ŸåŠ©å»å™ªæ¨¡å‹ä¼˜åŒ–ç›®æ ‡å‡½æ•°ï¼Œæå‡æ¨¡å‹å¯¹æ•°æ®åˆ†å¸ƒçš„æ•æ‰ä¸å»å™ªé‡å»ºèƒ½åŠ›ã€‚  

### ğŸ“ˆ å®éªŒç»“æœ
åœ¨åˆæˆå¼‚å¸¸æ•°æ®é›†å’ŒATLASæ•°æ®é›†çš„çœŸå®ç—…ç†ä¸Šè¯„ä¼°æ¨¡å‹å¼‚å¸¸æ£€æµ‹èƒ½åŠ›ï¼Œå®éªŒè¡¨æ˜ï¼šï¼ˆiï¼‰è¯¥æ¨¡å‹æŒç»­è¶…è¶Šå˜åˆ†è‡ªåŠ¨ç¼–ç å™¨ã€æ¡ä»¶å’Œæ— æ¡ä»¶æ½œåœ¨æ‰©æ•£æ¨¡å‹ï¼›ï¼ˆiiï¼‰åœ¨å¤§å¤šæ•°æ•°æ®é›†ä¸Šï¼Œè¶…è¿‡æœ‰é…å¯¹æ‚£ç—…/å¥åº·å›¾åƒçš„æœ‰ç›‘ç£ä¿®å¤æ–¹æ³•æ€§èƒ½ï¼Œå±•ç°äº†åœ¨3Dè„‘å›¾åƒå¼‚å¸¸æ£€æµ‹ä¸­çš„é«˜æ•ˆæ€§ã€‚  

### ğŸ’¬ å¯å€Ÿé‰´ä¹‹å¤„
1. å¼±ç›‘ç£ç»“åˆåˆæˆæ•°æ®çš„æ€è·¯ï¼šåœ¨æ•°æ®ç¨€ç¼ºåœºæ™¯ä¸‹ï¼Œåˆ©ç”¨åˆæˆä¼ªæ•°æ®è¾…åŠ©è®­ç»ƒï¼Œä¸ºåŒ»ç–—ç­‰æ•°æ®éš¾è·å–é¢†åŸŸæä¾›äº†æ•°æ®å¢å¼ºä¸è®­ç»ƒèŒƒå¼å‚è€ƒã€‚  
2. æµä½“é©±åŠ¨å¼‚å¸¸éšæœºåŒ–çš„ç”Ÿæˆæ–¹å¼ï¼šå°†ç‰©ç†è¿‡ç¨‹ï¼ˆå¹³æµ - æ‰©æ•£çš„PDEè¿‡ç¨‹ï¼‰å¼•å…¥å¼‚å¸¸ç”Ÿæˆï¼Œä¿éšœåˆæˆå¼‚å¸¸çš„åˆç†æ€§ï¼Œè¿™ç§è·¨å­¦ç§‘ç»“åˆç”ŸæˆçœŸå®æ•°æ®çš„æ–¹æ³•å€¼å¾—å€Ÿé‰´ã€‚  
3. åŸºäºæ‰©æ•£æ¨¡å‹æ”¹è¿›å¼‚å¸¸æ£€æµ‹ï¼šæ‰©æ•£æ¨¡å‹åœ¨æ•æ‰å¤æ‚æ•°æ®åˆ†å¸ƒä¸Šæœ‰ä¼˜åŠ¿ï¼Œæœ¬æ–‡é’ˆå¯¹åŒ»ç–—å›¾åƒåœºæ™¯æ”¹è¿›æ‰©æ•£æ¨¡å‹ç”¨äºå¼‚å¸¸æ£€æµ‹ï¼Œä¸ºæ‰©æ•£æ¨¡å‹åœ¨å‚ç›´é¢†åŸŸçš„åº”ç”¨æä¾›äº†å®è·µæ¡ˆä¾‹ã€‚

## cxr-lt-2024--a-miccai-challenge-on-long-tailed--multi-label--and-zero-shot-disease-classification-from-chest-x-ray
### Abstract
The CXR-LT series is a community-driven initiative designed to enhance lung
disease classification using chest X-rays (CXR). It tackles challenges in open
long-tailed lung disease classification and enhances the measurability of
state-of-the-art techniques. The first event, CXR-LT 2023, aimed to achieve
these goals by providing high-quality benchmark CXR data for model development
and conducting comprehensive evaluations to identify ongoing issues impacting
lung disease classification performance. Building on the success of CXR-LT
2023, the CXR-LT 2024 expands the dataset to 377,110 chest X-rays (CXRs) and 45
disease labels, including 19 new rare disease findings. It also introduces a
new focus on zero-shot learning to address limitations identified in the
previous event. Specifically, CXR-LT 2024 features three tasks: (i) long-tailed
classification on a large, noisy test set, (ii) long-tailed classification on a
manually annotated "gold standard" subset, and (iii) zero-shot generalization
to five previously unseen disease findings. This paper provides an overview of
CXR-LT 2024, detailing the data curation process and consolidating
state-of-the-art solutions, including the use of multimodal models for rare
disease detection, advanced generative approaches to handle noisy labels, and
zero-shot learning strategies for unseen diseases. Additionally, the expanded
dataset enhances disease coverage to better represent real-world clinical
settings, offering a valuable resource for future research. By synthesizing the
insights and innovations of participating teams, we aim to advance the
development of clinically realistic and generalizable diagnostic models for
chest radiography.
### ğŸŒŸ è®ºæ–‡è§£è¯» | CXR-LT 2024ï¼šèšç„¦èƒ¸éƒ¨Xå…‰çš„é•¿å°¾ã€å¤šæ ‡ç­¾ä¸é›¶æ ·æœ¬ç–¾ç—…åˆ†ç±»æŒ‘æˆ˜èµ›

### ğŸ“Œ èƒŒæ™¯ç—›ç‚¹/æœ¬æ–‡åŠ¨æœº
èƒ¸éƒ¨Xå…‰ï¼ˆCXRï¼‰æ˜¯è‚ºéƒ¨ç–¾ç—…è¯Šæ–­çš„é‡è¦å·¥å…·ï¼Œä½†å®é™…ä¸´åºŠä¸­ç–¾ç—…è¡¨ç°å­˜åœ¨**é•¿å°¾åˆ†å¸ƒ**ï¼ˆå¸¸è§ç–¾ç—…æ ·æœ¬å¤šã€ç½•è§ç–¾ç—…æ ·æœ¬æå°‘ï¼‰ã€éœ€è¦åŒæ—¶è¯†åˆ«**å¤šç±»ç–¾ç—…**ï¼Œä¸”è¿˜æœ‰å¤§é‡æœªè¢«ç°æœ‰æ•°æ®é›†è¦†ç›–çš„ç½•è§ç—…ç—‡ï¼Œå¯¼è‡´æ¨¡å‹å¯¹æ–°ç–¾ç—…çš„æ³›åŒ–èƒ½åŠ›ä¸è¶³ã€‚CXR-LTç³»åˆ—æ­£æ˜¯ä¸ºè§£å†³è¿™äº›é—®é¢˜è€Œç”Ÿçš„ç¤¾åŒºé©±åŠ¨é¡¹ç›®ï¼Œ2023å¹´çš„CXR-LTå·²æä¾›é«˜è´¨é‡åŸºå‡†æ•°æ®å¹¶æ¨åŠ¨äº†ç›¸å…³ç ”ç©¶ï¼Œä½†ä»éœ€åº”å¯¹â€œé›¶æ ·æœ¬å­¦ä¹ ï¼ˆæ¨¡å‹å¯¹å®Œå…¨æ²¡è§è¿‡çš„ç–¾ç—…ç±»åˆ«åšè¯†åˆ«ï¼‰â€ç­‰æ–°æŒ‘æˆ˜ã€‚å› æ­¤CXR-LT 2024åœ¨æ­¤åŸºç¡€ä¸Šè¿›ä¸€æ­¥æ‰©å±•æ•°æ®ã€è®¾è®¡ä»»åŠ¡ï¼Œæ¨åŠ¨è‚ºéƒ¨ç–¾ç—…åˆ†ç±»æŠ€æœ¯å‘æ›´è´´è¿‘çœŸå®ä¸´åºŠçš„æ–¹å‘å‘å±•ã€‚

### ğŸš€ æ ¸å¿ƒæ–¹æ³•ï¼ˆä»‹ç»æœ¬æ–‡çš„å‡ ä¸ªåˆ›æ–°ç‚¹ï¼‰
ğŸ’¡ åˆ›æ–°ç‚¹1ï¼šå¤§è§„æ¨¡ä¸”æ›´å…¨é¢çš„æ•°æ®é›†æ„å»º  
CXR-LT 2024å°†æ•°æ®é›†æ‰©å……åˆ°**377,110å¼ èƒ¸éƒ¨Xå…‰å›¾åƒ**ï¼Œæ¶µç›–45ä¸ªç–¾ç—…æ ‡ç­¾ï¼ˆæ–°å¢19ç§ç½•è§ç—…æ ‡ç­¾ï¼‰ã€‚ç›¸æ¯”2023å¹´ï¼Œæ•°æ®è§„æ¨¡ä¸ç–¾ç—…è¦†ç›–åº¦å¤§å¹…æå‡ï¼Œæ›´è´´è¿‘çœŸå®ä¸´åºŠä¸­ç–¾ç—…ç§ç±»ç¹æ‚ã€é•¿å°¾åˆ†å¸ƒçš„ç‰¹ç‚¹ï¼Œä¸ºæ¨¡å‹è®­ç»ƒä¸è¯„ä¼°æä¾›äº†æ›´ä¸°å¯Œçš„â€œç´ æâ€ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹2ï¼šä¸‰ç±»ä»»åŠ¡é’ˆå¯¹æ€§è§£å†³ä¸´åºŠéš¾ç‚¹  
æœ¬æ¬¡æŒ‘æˆ˜èµ›è®¾è®¡äº†ä¸‰é¡¹ä»»åŠ¡ï¼Œå…¨é¢è¦†ç›–é•¿å°¾å­¦ä¹ ä¸é›¶æ ·æœ¬å­¦ä¹ ç—›ç‚¹ï¼š  
- ä»»åŠ¡1ï¼šåœ¨**å¤§è§„æ¨¡å¸¦å™ªå£°æµ‹è¯•é›†**ä¸Šåšé•¿å°¾åˆ†ç±»â€”â€”æ¨¡æ‹ŸçœŸå®ä¸–ç•Œä¸­æ ‡ç­¾å¯èƒ½ä¸å‡†ç¡®ã€æ•°æ®åˆ†å¸ƒä¸å‡çš„åœºæ™¯ï¼›  
- ä»»åŠ¡2ï¼šåœ¨**äººå·¥æ ‡æ³¨çš„â€œé‡‘æ ‡å‡†â€å­é›†**ä¸Šåšé•¿å°¾åˆ†ç±»â€”â€”èšç„¦é«˜ç²¾åº¦æ ‡æ³¨ä¸‹çš„æ¨¡å‹æ€§èƒ½ï¼ŒéªŒè¯ç®—æ³•åœ¨å¹²å‡€æ•°æ®ä¸Šçš„ä¸Šé™ï¼›  
- ä»»åŠ¡3ï¼šå¯¹**5ç§å®Œå…¨æœªè§è¿‡çš„ç–¾ç—…**åšé›¶æ ·æœ¬æ³›åŒ–â€”â€”ç›´å‡»ä¸´åºŠä¸­â€œæ–°ç–¾ç—…æ— æ ‡æ³¨æ•°æ®å¯ç”¨â€çš„ç—›ç‚¹ï¼Œè¦æ±‚æ¨¡å‹å…·å¤‡è·¨æœªçŸ¥ç±»åˆ«çš„æ¨ç†èƒ½åŠ›ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹3ï¼šæ•´åˆå‰æ²¿æŠ€æœ¯æ–¹å‘çš„æ¢ç´¢  
è®ºæ–‡è¿˜æ¢³ç†äº†å‚èµ›å›¢é˜Ÿä¸é¢†åŸŸå†…åº”å¯¹è¿™äº›æŒ‘æˆ˜çš„å‰æ²¿æ€è·¯ï¼Œä¾‹å¦‚ï¼šç”¨**å¤šæ¨¡æ€æ¨¡å‹**è¾…åŠ©ç½•è§ç—…æ£€æµ‹ï¼ˆç»“åˆå›¾åƒã€æ–‡æœ¬ç­‰ä¿¡æ¯å¼¥è¡¥ç½•è§ç—…æ ·æœ¬å°‘çš„ç¼ºé™·ï¼‰ï¼›ç”¨**å…ˆè¿›ç”Ÿæˆå¼æ–¹æ³•**å¤„ç†å™ªå£°æ ‡ç­¾ï¼ˆç”Ÿæˆæ›´å¯é çš„æ ‡æ³¨æˆ–æ•°æ®å¢å¼ºï¼Œç¼“è§£æ ‡ç­¾å™ªå£°å¹²æ‰°ï¼‰ï¼›ä¸ºé›¶æ ·æœ¬ä»»åŠ¡è®¾è®¡**æ–°å‹å­¦ä¹ ç­–ç•¥**ï¼ˆè®©æ¨¡å‹å­¦ä¼šä»å·²çŸ¥ç±»åˆ«è¿ç§»çŸ¥è¯†åˆ°æœªçŸ¥ç±»åˆ«ï¼‰ã€‚  


### ğŸ“ˆ å®éªŒç»“æœ
æ–‡ä¸­è™½æœªå®Œå…¨å±•å¼€å„ä»»åŠ¡çš„æœ€ç»ˆç«èµ›æ’åç»†èŠ‚ï¼Œä½†ä»ä»»åŠ¡è®¾è®¡é€»è¾‘ä¸æŠ€æœ¯æ–¹å‘æ•´åˆæ¥çœ‹ï¼Œæ ¸å¿ƒåœ¨äºéªŒè¯ï¼š  
1. é•¿å°¾åœºæ™¯ä¸‹ï¼Œä¸åŒæ–¹æ³•ï¼ˆå¦‚æ•°æ®é‡é‡‡æ ·ã€æŸå¤±å‡½æ•°ä¼˜åŒ–ã€å¤šæ¨¡æ€èåˆç­‰ï¼‰å¯¹å¤šæ ‡ç­¾åˆ†ç±»æ€§èƒ½ï¼ˆä»¥mAPä¸ºæ ¸å¿ƒæŒ‡æ ‡ï¼Œè¾…ä»¥mAUROCã€mF1ã€ECEç­‰ï¼‰çš„æå‡æ•ˆæœï¼›  
2. é›¶æ ·æœ¬ä»»åŠ¡ä¸­ï¼Œæ¨¡å‹å¯¹å…¨æ–°ç–¾ç—…ç±»åˆ«çš„æ³›åŒ–èƒ½åŠ›ï¼ˆèƒ½å¦åŸºäºå°‘é‡å…ˆéªŒçŸ¥è¯†æˆ–è¯­ä¹‰ä¿¡æ¯ï¼Œè¯†åˆ«ä»æœªè®­ç»ƒè¿‡çš„ç–¾ç—…ï¼‰ï¼›  
3. äººå·¥æ ‡æ³¨â€œé‡‘æ ‡å‡†â€å­é›†ä¸å™ªå£°æµ‹è¯•é›†çš„å¯¹æ¯”ï¼Œèƒ½åæ˜ ç®—æ³•åœ¨â€œç†æƒ³-ç°å®â€åœºæ™¯ä¸‹çš„é²æ£’æ€§å·®å¼‚ã€‚  

è¿™äº›ä»»åŠ¡çš„è¯„ä¼°ä½“ç³»ï¼ˆå¤šæŒ‡æ ‡ç»“åˆï¼Œå…¼é¡¾æ•´ä½“ä¸ç»†ç²’åº¦ç±»åˆ«æ€§èƒ½ï¼‰ä¹Ÿä¸ºåç»­ç ”ç©¶æä¾›äº†â€œæ€ä¹ˆè¡¡é‡æ¨¡å‹å¥½åâ€çš„å‚è€ƒæ¡†æ¶ã€‚  


### ğŸ’¬ å¯å€Ÿé‰´ä¹‹å¤„
1. **æ•°æ®é›†å»ºè®¾æ€è·¯**ï¼šé€šè¿‡æŒç»­æ‰©å……çœŸå®ä¸–ç•Œç»´åº¦ï¼ˆç–¾ç—…è¦†ç›–ã€æ ·æœ¬è§„æ¨¡ï¼‰çš„æ•°æ®é›†ï¼Œæ¨åŠ¨é¢†åŸŸç ”ç©¶æ›´è´´è¿‘ä¸´åºŠâ€”â€”è¿™å¯¹åŒ»ç–—AIç±»ç ”ç©¶æå…·å‚è€ƒæ€§ï¼Œæ¯•ç«ŸçœŸå®åœºæ™¯çš„æ•°æ®å¤æ‚æ€§è¿œéå°æ•°æ®é›†èƒ½è¦†ç›–ï¼›  
2. **ä»»åŠ¡è®¾è®¡èŒƒå¼**ï¼šç”¨â€œå™ªå£°æµ‹è¯•é›†+é‡‘æ ‡å‡†å­é›†+é›¶æ ·æœ¬ä»»åŠ¡â€çš„ç»„åˆæ‹³ï¼ŒæŠŠé•¿å°¾å­¦ä¹ ã€é²æ£’æ€§ã€æ³›åŒ–æ€§ç­‰éš¾ç‚¹æ‹†è§£æˆå¯é‡åŒ–çš„ç«èµ›ä»»åŠ¡ï¼Œè¿™ç§â€œåˆ†åœºæ™¯æ‹†è§£é—®é¢˜â€çš„æ€è·¯ï¼Œèƒ½å¸®åŠ©ç ”ç©¶è€…æ›´ç²¾å‡†åœ°è¿­ä»£ç®—æ³•ï¼›  
3. **æŠ€æœ¯æ–¹å‘å¯å‘**ï¼šå¤šæ¨¡æ€èåˆã€ç”Ÿæˆå¼æ–¹æ³•å¤„ç†å™ªå£°ã€é›¶æ ·æœ¬å­¦ä¹ ç­–ç•¥ç­‰ï¼Œéƒ½æ˜¯AIåŒ»ç–—é¢†åŸŸçªç ´æ•°æ®ç“¶é¢ˆçš„å…³é”®æ–¹å‘ã€‚è®ºæ–‡æ•´åˆè¿™äº›å‰æ²¿å°è¯•ï¼Œä¸ºåæ¥è€…æŒ‡æ˜äº†â€œä»å“ªäº›è§’åº¦æ”¹è¿›æ¨¡å‹â€çš„è·¯å¾„ï¼›  
4. **è¯„ä¼°æŒ‡æ ‡é€‰æ‹©**ï¼šåœ¨é•¿å°¾å¤šæ ‡ç­¾åœºæ™¯ä¸‹ï¼Œæ”¾å¼ƒå•ä¸€AUROCæŒ‡æ ‡ï¼Œæ”¹ç”¨mAPä¸ºä¸»ã€å¤šæŒ‡æ ‡ä¸ºè¾…çš„è¯„ä¼°ä½“ç³»â€”â€”è¿™æé†’æˆ‘ä»¬ï¼šä¸åŒåœºæ™¯ä¸‹â€œé€‰å¯¹è¯„ä¼°æŒ‡æ ‡â€æ‰èƒ½çœŸå®åæ˜ æ¨¡å‹ä»·å€¼ï¼Œé¿å…æŒ‡æ ‡é€šèƒ€å¸¦æ¥çš„è¯¯å¯¼ã€‚  


CXR-LT 2024ä¸ä»…æ˜¯ä¸€åœºç«èµ›ï¼Œæ›´æ˜¯ä¸€æ¬¡â€œæŠŠä¸´åºŠç—›ç‚¹è½¬åŒ–ä¸ºç§‘ç ”é—®é¢˜ã€ç”¨å¤§è§„æ¨¡æ•°æ®ä¸åˆ›æ–°ä»»åŠ¡æ¨åŠ¨æŠ€æœ¯è½åœ°â€çš„å…¸èŒƒå®è·µï¼Œä¸ºèƒ¸éƒ¨Xå…‰è¯Šæ–­ä¹ƒè‡³æ›´å¹¿æ³›çš„åŒ»ç–—AIç ”ç©¶æä¾›äº†æ•°æ®é›†ã€ä»»åŠ¡è®¾è®¡ã€æŠ€æœ¯è·¯çº¿ä¸è¯„ä¼°æ–¹æ³•çš„å…¨æ–¹ä½å‚è€ƒã€‚

## casereportbench--an-llm-benchmark-dataset-for-dense-information-extraction-in-clinical-case-reports
### Abstract
Rare diseases, including Inborn Errors of Metabolism (IEM), pose significant
diagnostic challenges. Case reports serve as key but computationally
underutilized resources to inform diagnosis. Clinical dense information
extraction refers to organizing medical information into structured predefined
categories. Large Language Models (LLMs) may enable scalable information
extraction from case reports but are rarely evaluated for this task. We
introduce CaseReportBench, an expert-annotated dataset for dense information
extraction of case reports, focusing on IEMs. Using this dataset, we assess
various models and prompting strategies, introducing novel approaches such as
category-specific prompting and subheading-filtered data integration. Zero-shot
chain-of-thought prompting offers little advantage over standard zero-shot
prompting. Category-specific prompting improves alignment with the benchmark.
The open-source model Qwen2.5-7B outperforms GPT-4o for this task. Our
clinician evaluations show that LLMs can extract clinically relevant details
from case reports, supporting rare disease diagnosis and management. We also
highlight areas for improvement, such as LLMs' limitations in recognizing
negative findings important for differential diagnosis. This work advances
LLM-driven clinical natural language processing and paves the way for scalable
medical AI applications.
### ğŸŒŸ è®ºæ–‡è§£è¯» | CaseReportBenchï¼šé¢å‘ä¸´åºŠç—…ä¾‹æŠ¥å‘Šå¯†é›†ä¿¡æ¯æŠ½å–çš„å¤§æ¨¡å‹åŸºå‡†æ•°æ®é›†

### ğŸ“Œ èƒŒæ™¯ç—›ç‚¹/æœ¬æ–‡åŠ¨æœº
ç½•è§ç—…ï¼ˆå¦‚å…ˆå¤©æ€§ä»£è°¢é”™è¯¯ç–¾ç—…IEMï¼‰è¯Šæ–­éš¾åº¦å¤§ï¼Œç—…ä¾‹æŠ¥å‘Šæ˜¯é‡è¦è¯Šæ–­å‚è€ƒèµ„æºä½†åœ¨è®¡ç®—å±‚é¢æœªå……åˆ†åˆ©ç”¨ã€‚ä¸´åºŠå¯†é›†ä¿¡æ¯æŠ½å–éœ€å°†åŒ»ç–—ä¿¡æ¯ç»„ç»‡æˆç»“æ„åŒ–é¢„å®šä¹‰ç±»åˆ«ï¼Œå¤§è¯­è¨€æ¨¡å‹ï¼ˆLLMsï¼‰è™½æœ‰æ½œåŠ›ä»ç—…ä¾‹æŠ¥å‘Šä¸­è§„æ¨¡åŒ–æå–ä¿¡æ¯ï¼Œå´å¾ˆå°‘é’ˆå¯¹è¯¥ä»»åŠ¡è¯„ä¼°ã€‚å› æ­¤ï¼Œæœ¬æ–‡æ—¨åœ¨æ„å»ºç”¨äºç—…ä¾‹æŠ¥å‘Šå¯†é›†ä¿¡æ¯æŠ½å–çš„åŸºå‡†ï¼Œèšç„¦IEMï¼Œæ¢ç´¢æœ‰æ•ˆLLMæ–¹æ³•ã€‚

### ğŸš€ æ ¸å¿ƒæ–¹æ³•ï¼ˆä»‹ç»æœ¬æ–‡çš„å‡ ä¸ªåˆ›æ–°ç‚¹ï¼‰
ğŸ’¡ åˆ›æ–°ç‚¹1ï¼šæ„å»ºCaseReportBenchæ•°æ®é›†  
æ‰“é€ ç”±ä¸“å®¶æ ‡æ³¨ã€é’ˆå¯¹ç—…ä¾‹æŠ¥å‘Šï¼ˆèšç„¦IEMï¼‰å¯†é›†ä¿¡æ¯æŠ½å–çš„åŸºå‡†æ•°æ®é›†ï¼Œä¸ºè¯„ä¼°å¤§æ¨¡å‹åœ¨è¯¥åœºæ™¯ä¸‹è¡¨ç°æä¾›åŸºç¡€ï¼Œè¿˜å…¬å¼€æ•°æ®é›†ï¼ˆHugging Faceï¼‰ä¸ä»£ç ï¼ˆGitHubï¼‰ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹2ï¼šæ¢ç´¢å¤šæ ·æç¤ºä¸æ•°æ®æ•´åˆç­–ç•¥  
è¯„ä¼°ä¸åŒæç¤ºå’Œæ•°æ®æ•´åˆç­–ç•¥ç”¨äºå¯†é›†ä¿¡æ¯æŠ½å–ï¼Œæå‡ºç±»åˆ«ç‰¹å®šæŠ½å–æç¤ºï¼ˆcategory - specific extraction promptingï¼‰ã€å­æ ‡é¢˜è¿‡æ»¤æ–¹æ³•ï¼ˆsubheading - filtered approachï¼‰ç­‰æ–°æŠ€æœ¯ï¼Œæå‡å¤§æ¨¡å‹å¯†é›†ä¿¡æ¯æŠ½å–æ•ˆæœã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹3ï¼šå¼€å±•ä¸´åºŠè¯„ä¼°  
å¯¹å¤§æ¨¡å‹æŠ½å–è¾“å‡ºåšä¸´åºŠè¯„ä¼°ï¼ŒéªŒè¯å…¶å‡å°‘äººå·¥æŠ½å–å·¥ä½œé‡æ½œåŠ›çš„åŒæ—¶ï¼Œæ˜ç¡®å­˜åœ¨çš„æŒ‘æˆ˜ã€‚  

### ğŸ“ˆ å®éªŒç»“æœ
é›¶æ ·æœ¬æ€ç»´é“¾æç¤ºè¾ƒæ ‡å‡†é›¶æ ·æœ¬æç¤ºä¼˜åŠ¿ä¸å¤§ï¼›ç±»åˆ«ç‰¹å®šæç¤ºæå‡ä¸åŸºå‡†çš„ä¸€è‡´æ€§ï¼›å¼€æºæ¨¡å‹Qwen2.5 - 7Båœ¨è¯¥ä»»åŠ¡ä¸Šè¡¨ç°ä¼˜äºGPT - 4oï¼›ä¸´åºŠè¯„ä¼°æ˜¾ç¤ºå¤§æ¨¡å‹èƒ½æå–ç—…ä¾‹æŠ¥å‘Šä¸­ä¸´åºŠç›¸å…³ç»†èŠ‚è¾…åŠ©ç½•è§ç—…è¯Šç–—ï¼Œä½†åœ¨è¯†åˆ«é‰´åˆ«è¯Šæ–­å…³é”®çš„é˜´æ€§ç»“æœç­‰æ–¹é¢å­˜åœ¨ä¸è¶³ã€‚  

### ğŸ’¬ å¯å€Ÿé‰´ä¹‹å¤„
åœ¨åŒ»ç–—NLPé¢†åŸŸï¼Œä¸ºåŸºäºå¤§æ¨¡å‹çš„ä¸´åºŠå¯†é›†ä¿¡æ¯æŠ½å–ä»»åŠ¡æä¾›äº†æ–°åŸºå‡†æ•°æ®é›†ä¸è¯„ä¼°æ–¹æ³•å‚è€ƒï¼›æå‡ºçš„ç±»åˆ«ç‰¹å®šæç¤ºç­‰ç­–ç•¥ä¸ºä¼˜åŒ–å¤§æ¨¡å‹åœ¨å‚ç›´é¢†åŸŸä¿¡æ¯æŠ½å–æ•ˆæœæä¾›æ€è·¯ï¼›å…¬å¼€æ•°æ®é›†ä¸ä»£ç åˆ©äºè¡Œä¸šåç»­ç ”ç©¶å¤ç°ä¸æ‹“å±•ï¼Œæ¨åŠ¨åŒ»ç–—AIè§„æ¨¡åŒ–åº”ç”¨å‘å±•ã€‚

## decoding-rarity--large-language-models-in-the-diagnosis-of-rare-diseases
### Abstract
Recent advances in artificial intelligence, particularly large language
models LLMs, have shown promising capabilities in transforming rare disease
research. This survey paper explores the integration of LLMs in the analysis of
rare diseases, highlighting significant strides and pivotal studies that
leverage textual data to uncover insights and patterns critical for diagnosis,
treatment, and patient care. While current research predominantly employs
textual data, the potential for multimodal data integration combining genetic,
imaging, and electronic health records stands as a promising frontier. We
review foundational papers that demonstrate the application of LLMs in
identifying and extracting relevant medical information, simulating intelligent
conversational agents for patient interaction, and enabling the formulation of
accurate and timely diagnoses. Furthermore, this paper discusses the challenges
and ethical considerations inherent in deploying LLMs, including data privacy,
model transparency, and the need for robust, inclusive data sets. As part of
this exploration, we present a section on experimentation that utilizes
multiple LLMs alongside structured questionnaires, specifically designed for
diagnostic purposes in the context of different diseases. We conclude with
future perspectives on the evolution of LLMs towards truly multimodal
platforms, which would integrate diverse data types to provide a more
comprehensive understanding of rare diseases, ultimately fostering better
outcomes in clinical settings.
### ğŸŒŸ è®ºæ–‡è§£è¯» | è§£ç ç½•è§ç—…ï¼šå¤§è¯­è¨€æ¨¡å‹åœ¨ç½•è§ç—…è¯Šæ–­ä¸­çš„åº”ç”¨

### ğŸ“Œ èƒŒæ™¯ç—›ç‚¹/æœ¬æ–‡åŠ¨æœº
ç½•è§ç—…è™½å•ä¸ªç–¾ç—…æ‚£ç—…ç‡ä½ï¼Œä½†æ•´ä½“å½±å“äººç¾¤è§„æ¨¡å¤§ï¼ˆå…¨çƒçº¦3.5%-5.9%äººå£å—å½±å“ï¼‰ï¼Œä¸”å­˜åœ¨è¯¸å¤šç ”ç©¶ä¸è¯Šç–—æŒ‘æˆ˜ã€‚æ‚£è€…å¸¸é¢ä¸´æ¼«é•¿ä¸”å¤æ‚çš„è¯Šæ–­è¿‡ç¨‹ï¼Œæ˜“è¢«è¯¯è¯Šæˆ–å»¶è¿Ÿè¯Šæ–­ï¼›ç–¾ç—…ç ”ç©¶æ–¹é¢ï¼Œå­˜åœ¨æ‚£è€…æ•°æ®ç¨€ç¼ºã€çŸ¥è¯†ç¢ç‰‡åŒ–ã€æ²»ç–—ç ”å‘æ»åç­‰é—®é¢˜ã€‚æ­¤å‰å¤§è¯­è¨€æ¨¡å‹ï¼ˆLLMsï¼‰åœ¨ç½•è§ç—…é¢†åŸŸåº”ç”¨é›¶æ•£ä¸”ç¼ºä¹å…¨é¢åˆ»ç”»ï¼Œå› æ­¤æœ¬æ–‡æ—¨åœ¨ç³»ç»Ÿç»¼è¿°LLMsåœ¨ç½•è§ç—…è¯Šæ–­ã€ç–¾ç—…æœºåˆ¶é˜æ˜åŠæ²»ç–—ç­–ç•¥æŒ‡å¯¼ç­‰æ–¹é¢çš„åº”ç”¨ï¼Œæ¢ç´¢å¤šæ¨¡æ€æ•´åˆæ½œåŠ›ï¼Œä¸ºç›¸å…³ç ”ç©¶ä¸å®è·µæä¾›æŒ‡å¼•ã€‚

### ğŸš€ æ ¸å¿ƒæ–¹æ³•ï¼ˆä»‹ç»æœ¬æ–‡çš„å‡ ä¸ªåˆ›æ–°ç‚¹ï¼‰
ğŸ’¡ åˆ›æ–°ç‚¹1ï¼šå…¨é¢ç»¼è¿°LLMsåœ¨ç½•è§ç—…é¢†åŸŸåº”ç”¨  
å›é¡¾å±•ç¤ºLLMsåœ¨è¯†åˆ«æå–åŒ»ç–—ä¿¡æ¯ã€æ¨¡æ‹Ÿæ‚£è€…äº¤äº’æ™ºèƒ½å¯¹è¯ä»£ç†ã€åŠ©åŠ›ç²¾å‡†åŠæ—¶è¯Šæ–­ç­‰æ–¹é¢åº”ç”¨çš„åŸºç¡€è®ºæ–‡ï¼Œæ¢³ç†å½“å‰LLMsåœ¨ç½•è§ç—…åˆ†æä¸­åˆ©ç”¨æ–‡æœ¬æ•°æ®æŒ–æ˜è¯Šæ–­ã€æ²»ç–—å’Œæ‚£è€…æŠ¤ç†å…³é”®æ¨¡å¼ä¸è§è§£çš„è¿›å±•ã€‚  
ğŸ’¡ åˆ›æ–°ç‚¹2ï¼šæ¢ç´¢å¤šæ¨¡æ€æ•°æ®æ•´åˆå‰æ™¯  
æŒ‡å‡ºå½“å‰ç ”ç©¶å¤šé‡‡ç”¨æ–‡æœ¬æ•°æ®ï¼Œä½†ç»“åˆåŸºå› ã€å½±åƒã€ç”µå­å¥åº·è®°å½•ç­‰å¤šæ¨¡æ€æ•°æ®æ•´åˆæ˜¯æå…·æ½œåŠ›çš„å‰æ²¿æ–¹å‘ï¼Œæ¢è®¨å…¶å¯¹æ¨è¿›ä¸ªæ€§åŒ–åŒ»ç–—å’Œæ”¹å–„æ‚£è€…é¢„åçš„å¯èƒ½ã€‚  
ğŸ’¡ åˆ›æ–°ç‚¹3ï¼šå…³æ³¨éƒ¨ç½²æŒ‘æˆ˜ä¸ä¼¦ç†è€ƒé‡  
æ·±å…¥è®¨è®ºLLMséƒ¨ç½²ä¸­çš„æ•°æ®éšç§ã€æ¨¡å‹é€æ˜åº¦ã€éœ€å¼ºå¥ä¸”å…·åŒ…å®¹æ€§æ•°æ®é›†ç­‰æŒ‘æˆ˜ä¸ä¼¦ç†é—®é¢˜ï¼Œä¸ºè´Ÿè´£ä»»ä½¿ç”¨æä¾›æ€è€ƒã€‚  
ğŸ’¡ åˆ›æ–°ç‚¹4ï¼šå¼€å±•ç‰¹å®šå®éªŒæ¢ç´¢  
è®¾ç½®åˆ©ç”¨å¤šä¸ªLLMsç»“åˆä¸ºä¸åŒç–¾ç—…è¯Šæ–­è®¾è®¡çš„ç»“æ„åŒ–é—®å·è¿›è¡Œå®éªŒçš„éƒ¨åˆ†ï¼Œæ¢ç´¢è¯Šæ–­åœºæ™¯ä¸‹LLMsåº”ç”¨æ–¹å¼ã€‚  

### ğŸ“ˆ å®éªŒç»“æœ
æ–‡ä¸­æœªè¯¦ç»†å‘ˆç°å®éªŒå®šé‡ç»“æœï¼ˆåŸæ–‡ä¸­å®éªŒéƒ¨åˆ†æœªå®Œæ•´å±•ç¤ºï¼‰ï¼Œä½†ä»æ•´ä½“é€»è¾‘çœ‹ï¼Œé€šè¿‡å¯¹æ–‡çŒ®çš„ç³»ç»Ÿæ¢³ç†ï¼ˆéµå¾ªPRISMAæŒ‡å—ï¼Œä»è¯†åˆ«75ç¯‡æ–‡çŒ®åˆ°ç­›é€‰ååˆ†æç­‰æµç¨‹ï¼‰ï¼Œæ˜ç¡®äº†LLMsåœ¨ç½•è§ç—…é¢†åŸŸç°æœ‰åº”ç”¨åœºæ™¯ã€å¤šæ¨¡æ€ç­‰å‘å±•æ–¹å‘ä»·å€¼ä»¥åŠé¢ä¸´çš„æŒ‘æˆ˜ç­‰ï¼Œä¸ºè¯¥é¢†åŸŸåç»­ç ”ç©¶å’Œå®è·µæä¾›äº†æ¸…æ™°çš„ç°çŠ¶åœ°å›¾ä¸æ–¹å‘æŒ‡å¼•ã€‚  

### ğŸ’¬ å¯å€Ÿé‰´ä¹‹å¤„
1. ç³»ç»Ÿç»¼è¿°æ€è·¯ï¼šé‡‡ç”¨PRISMAæŒ‡å—è¿›è¡Œæ–‡çŒ®ç­›é€‰åˆ†æï¼Œä¸ºé¢†åŸŸå†…ç³»ç»Ÿæ€§æ¢³ç†ç ”ç©¶ç°çŠ¶æä¾›äº†å¯å‚è€ƒçš„æ–¹æ³•è®ºï¼Œæœ‰åŠ©äºåç»­ç±»ä¼¼ä¸»é¢˜ç»¼è¿°ç±»ç ”ç©¶å¼€å±•ã€‚  
2. å¤šç»´åº¦åˆ†æè§†è§’ï¼šä»åº”ç”¨åœºæ™¯ã€æ•°æ®æ•´åˆã€æŒ‘æˆ˜ä¼¦ç†ã€å®éªŒæ¢ç´¢ç­‰å¤šç»´åº¦å‰–æLLMsä¸ç½•è§ç—…è¯Šç–—ç»“åˆï¼Œèƒ½è®©è¯»è€…å…¨é¢ç†è§£è¯¥é¢†åŸŸç°çŠ¶ä¸æ–¹å‘ï¼Œå…¶ä»–åŒ»ç–—AIäº¤å‰é¢†åŸŸç ”ç©¶ä¹Ÿå¯å€Ÿé‰´è¿™ç§å¤šç»´åº¦åˆ†ææ¡†æ¶ã€‚  
3. å‰æ²¿æ–¹å‘æ´å¯Ÿï¼šå¯¹å¤šæ¨¡æ€æ•°æ®æ•´åˆç­‰å‰æ²¿æ–¹å‘çš„å¼ºè°ƒï¼Œä¸ºç§‘ç ”äººå‘˜å’Œä»ä¸šè€…æŒ‡æ˜äº†æœªæ¥æŠ€æœ¯èåˆçš„æ½œåŠ›ç‚¹ï¼Œåˆ©äºå¼•å¯¼èµ„æºæŠ•å…¥å’Œç ”ç©¶æ–¹å‘é€‰æ‹©ã€‚

## modis--multi-omics-data-integration-for-small-and-unpaired-datasets
### Abstract
A key challenge today lies in the ability to efficiently handle multi-omics
data since such multimodal data may provide a more comprehensive overview of
the underlying processes in a system. Yet it comes with challenges: multi-omics
data are most often unpaired and only partially labeled, moreover only small
amounts of data are available in some situation such as rare diseases. We
propose MODIS which stands for Multi-Omics Data Integration for Small and
unpaired datasets, a semi supervised approach to account for these particular
settings. MODIS learns a probabilistic coupling of heterogeneous data
modalities and learns a shared latent space where modalities are aligned. We
rely on artificial data to build controlled experiments to explore how much
supervision is needed for an accurate alignment of modalities, and how our
approach enables dealing with new conditions for which few data are available.
The code is available athttps://github.com/VILLOUTREIXLab/MODIS.
### ğŸŒŸ è®ºæ–‡è§£è¯» | MODISï¼šå°æ ·æœ¬ä¸éé…å¯¹å¤šç»„å­¦æ•°æ®çš„æ•´åˆæ–°æ–¹æ¡ˆ

### ğŸ“Œ èƒŒæ™¯ç—›ç‚¹/æœ¬æ–‡åŠ¨æœº
åœ¨ç†è§£å¤æ‚ç”Ÿç‰©æœºåˆ¶ä¸è§£å†³è¯Šæ–­éš¾é¢˜ï¼ˆå¦‚ç½•è§ç—…è¯Šæ–­ï¼‰æ—¶ï¼Œå¤šç»„å­¦æ•°æ®èƒ½æä¾›æ›´å…¨é¢è§†è§’ï¼Œä½†å¤„ç†å¤šç»„å­¦æ•°æ®å­˜åœ¨è¯¸å¤šæŒ‘æˆ˜ï¼šæ•°æ®å¾€å¾€æ˜¯éé…å¯¹çš„ã€ä»…éƒ¨åˆ†å¸¦æ ‡ç­¾ï¼Œä¸”åœ¨ç½•è§ç—…ç­‰åœºæ™¯ä¸‹æ•°æ®é‡æå°‘ã€‚ç°æœ‰å¤šç»„å­¦æ•´åˆæ–¹æ³•å¤§å¤šä¾èµ–å¤§è§„æ¨¡æ•°æ®é›†è®­ç»ƒï¼Œéš¾ä»¥ç›´æ¥åº”ç”¨äºæ ·æœ¬å°‘ã€æ¨¡æ€éé…å¯¹ç”šè‡³éƒ¨åˆ†æ¨¡æ€ç¼ºå¤±çš„ç½•è§ç—…ç­‰åœºæ™¯ã€‚å› æ­¤ï¼ŒäºŸéœ€ä¸€ç§èƒ½åº”å¯¹å°æ ·æœ¬ã€éé…å¯¹å¤šç»„å­¦æ•°æ®æ•´åˆçš„æ–¹æ³•ï¼Œè¿™æ­£æ˜¯æœ¬æ–‡æå‡ºMODISçš„åŠ¨æœºã€‚

### ğŸš€ æ ¸å¿ƒæ–¹æ³•ï¼ˆä»‹ç»æœ¬æ–‡çš„å‡ ä¸ªåˆ›æ–°ç‚¹ï¼‰
ğŸ’¡ åˆ›æ–°ç‚¹1ï¼šåŠç›‘ç£çš„å¤šç»„å­¦æ•´åˆæ¡†æ¶  
MODISæ˜¯é¢å‘å°æ ·æœ¬å’Œéé…å¯¹æ•°æ®é›†çš„åŠç›‘ç£å¤šç»„å­¦æ•°æ®æ•´åˆæ–¹æ³•ã€‚å®ƒå­¦ä¹ å¼‚è´¨æ•°æ®æ¨¡æ€é—´çš„æ¦‚ç‡è€¦åˆå…³ç³»ï¼Œå¹¶æ„å»ºä¸€ä¸ªå…±äº«æ½œåœ¨ç©ºé—´æ¥å¯¹é½ä¸åŒæ¨¡æ€ã€‚é€šè¿‡è¿™ç§æ–¹å¼ï¼Œèƒ½åœ¨æ•°æ®éé…å¯¹ã€æ ‡ç­¾ä¸å®Œæ•´çš„æƒ…å†µä¸‹ï¼Œå®ç°å¤šæ¨¡æ€çš„æœ‰æ•ˆæ•´åˆä¸å…³è”ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹2ï¼šåˆ©ç”¨å‚è€ƒæ•°æ®é›†è¾…åŠ©å°æ•°æ®é›†å¯¹é½  
å€ŸåŠ©å¤§è§„æ¨¡å‚è€ƒæ•°æ®é›†ï¼ˆå¦‚TCGAæ•°æ®åº“ï¼‰ä¸å°ç›®æ ‡æ•°æ®é›†ï¼ˆå¦‚ç½•è§ç—…æ•°æ®ï¼‰ç»“åˆè®­ç»ƒã€‚åˆ©ç”¨ä»å¤§è§„æ¨¡æ•°æ®ä¸­å­¦åˆ°çš„ç»“æ„ï¼ŒåŠ©åŠ›å°æ•°æ®é›†ä¸­æ¨¡æ€çš„å¯¹é½ä¸ç¿»è¯‘ï¼Œä»¥åŠæ ‡ç­¾åˆ†ç±»ä»»åŠ¡ï¼Œè§£å†³å°æ ·æœ¬åœºæ™¯ä¸‹æ•°æ®ä¸è¶³çš„é—®é¢˜ã€‚  

ğŸ’¡ åˆ›æ–°ç‚¹3ï¼šåº”å¯¹å¤šåœºæ™¯éœ€æ±‚çš„æ¨¡å‹è®¾è®¡  
è€ƒè™‘åˆ°å®é™…åœºæ™¯ä¸­å¸¸å‡ºç°çš„æƒ…å†µï¼ˆå¦‚ä»…å•ä¸ªæ¨¡æ€æ•°æ®å¯ç”¨ã€å­˜åœ¨æœªæ ‡è®°æ•°æ®ã€éƒ¨åˆ†ç±»åˆ«è®­ç»ƒæ ·æœ¬å°‘ç­‰ï¼‰ï¼ŒMODISè®¾è®¡ä¸Šæ”¯æŒå•æ¨¡æ€æ ·æœ¬çš„ç±»åˆ«é¢„æµ‹ã€åˆ©ç”¨æ— æ ‡ç­¾æ•°æ®ä»¥åŠå¤„ç†ç±»åˆ«ä¸å¹³è¡¡çš„åˆ†ç±»é—®é¢˜ï¼Œå…¨é¢è¦†ç›–å¤šç»„å­¦å°æ ·æœ¬åœºæ™¯ä¸‹çš„æ ¸å¿ƒéœ€æ±‚ã€‚  

### ğŸ“ˆ å®éªŒç»“æœ
è®ºæ–‡å€ŸåŠ©äººå·¥æ•°æ®æ„å»ºå—æ§å®éªŒï¼Œæ¢ç´¢æ¨¡æ€å‡†ç¡®å¯¹é½æ‰€éœ€çš„ç›‘ç£ç¨‹åº¦ï¼Œä»¥åŠè¯¥æ–¹æ³•åœ¨å°‘é‡æ•°æ®å¯ç”¨çš„æ–°åœºæ™¯ä¸‹çš„åº”å¯¹èƒ½åŠ›ã€‚é€šè¿‡è¿™äº›å®éªŒéªŒè¯MODISåœ¨å°æ ·æœ¬ã€éé…å¯¹å¤šç»„å­¦æ•°æ®æ•´åˆä¸ç›¸å…³ä»»åŠ¡ï¼ˆå¦‚åˆ†ç±»ï¼‰ä¸­çš„æœ‰æ•ˆæ€§ï¼Œä½†åŸæ–‡æœªè¯¦ç»†å±•å¼€å…·ä½“å®éªŒæ•°å€¼ç»“æœï¼Œé‡ç‚¹åœ¨äºæ–¹æ³•è®¾è®¡ä¸å®éªŒæ€è·¯çš„å‘ˆç°ã€‚  

### ğŸ’¬ å¯å€Ÿé‰´ä¹‹å¤„
1. å¤šæ¨¡æ€æ•´åˆæ€è·¯ï¼šé’ˆå¯¹å¤šç»„å­¦è¿™ç±»å…¸å‹å¤šæ¨¡æ€æ•°æ®ï¼Œæå‡ºçš„æ¦‚ç‡è€¦åˆä¸å…±äº«æ½œåœ¨ç©ºé—´æ„å»ºæ–¹å¼ï¼Œä¸ºå…¶ä»–é¢†åŸŸï¼ˆå¦‚è§†å¬å¤šæ¨¡æ€ã€æ–‡æœ¬å›¾åƒå¤šæ¨¡æ€ç­‰ï¼‰çš„å°æ ·æœ¬éé…å¯¹æ•°æ®æ•´åˆæä¾›äº†å‚è€ƒèŒƒå¼ã€‚  
2. å°æ ·æœ¬åœºæ™¯è§£æ³•ï¼šåˆ©ç”¨å¤§è§„æ¨¡å‚è€ƒæ•°æ®è¾…åŠ©å°æ•°æ®é›†å­¦ä¹ çš„ç­–ç•¥ï¼Œåœ¨åŒ»ç–—ã€å°ä¼—é¢†åŸŸç­‰æ•°æ®ç¨€ç¼ºåœºæ™¯ä¸‹ï¼Œä¸ºæ¨¡å‹è®­ç»ƒä¸æ€§èƒ½æå‡æä¾›äº†å¯è¡Œæ€è·¯ï¼Œå¯è¿ç§»åˆ°ç±»ä¼¼æ•°æ®åˆ†å¸ƒä¸å‡ã€å°æ ·æœ¬çš„ä»»åŠ¡ä¸­ã€‚  
3. åŠç›‘ç£ä¸å¤šéœ€æ±‚è¦†ç›–ï¼šåœ¨æ¨¡å‹ä¸­å…¼é¡¾åŠç›‘ç£å­¦ä¹ ï¼ˆåˆ©ç”¨æ— æ ‡ç­¾æ•°æ®ï¼‰ã€å¤šæ¨¡æ€å•æ¨¡æ€é¢„æµ‹ã€ç±»åˆ«ä¸å¹³è¡¡å¤„ç†ç­‰ï¼Œè¿™ç§å…¨é¢è¦†ç›–å®é™…åœºæ™¯éœ€æ±‚çš„è®¾è®¡ç†å¿µï¼Œå¯¹è§£å†³å¤æ‚ç°å®ä»»åŠ¡æœ‰å¾ˆå¥½çš„å€Ÿé‰´æ„ä¹‰ï¼Œæé†’ç ”ç©¶è€…åœ¨æ–¹æ³•è®¾è®¡æ—¶å……åˆ†è€ƒè™‘çœŸå®åœºæ™¯çš„å¤šæ ·æ€§çº¦æŸã€‚

